{"fetched":"2026-10-23","note":"Regulators, trials and research output outside the US and the English-speaking world. Nothing here is machine-translated: sources are used in the English their own publisher provides, and names that are not in English are marked.","regulators":{"canada":{"source":"https://health-products.canada.ca/api/drug/drugproduct/?lang=en","total":163,"marketed":58,"rows":[{"name":"[F-18]-FLUDEOXYGLUCOSE (FDG) INJECTION","company":"SYLVIA FEDORUK CANADIAN CENTRE FOR NUCLEAR INNOVATION","date":"2025-03-22","status":"Marketed","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94822","refs":[]},{"name":"131I-MIBG","company":"DRAXIMAGE A DIVISION OF DRAXIS SPECIALTY PHARMACEUTICALS INC","date":"2025-03-22","status":"Cancelled Pre Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83475","refs":["iobenguane-i-131","i-131"]},{"name":"131I-MIBG","company":"HAMILTON HEALTH SCIENCES CORPORATION","date":"2025-03-22","status":"Cancelled Pre Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83477","refs":["iobenguane-i-131","i-131"]},{"name":"18F-FLUDEOXYGLUCOSE (18F-FDG)","company":"ISOLOGIC INNOVATIVE RADIOPHARMACEUTICALS LTD.","date":"2025-03-22","status":"Marketed","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81437","refs":["f-18-fdg-brain"]},{"name":"99MTC SULPHIDE COLLOID KIT","company":"ISOLOGIC INNOVATIVE RADIOPHARMACEUTICALS LTD.","date":"2025-03-22","status":"Cancelled Pre Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83986","refs":["tc-99m"]},{"name":"ADREVIEW","company":"GE HEALTHCARE CANADA INC","date":"2025-03-22","status":"Marketed","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87259","refs":["i-123-mibg-cardiac","i-123-mibg"]},{"name":"AMERSCAN MEDRONATE II","company":"GE HEALTHCARE CANADA INC","date":"2025-03-22","status":"Cancelled Pre Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81442","refs":[]},{"name":"AMERSCAN PENTETATE II","company":"GE HEALTHCARE CANADA INC","date":"2025-03-22","status":"Cancelled Pre Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81583","refs":[]},{"name":"ANTIMONY SULFIDE COLLOID KIT","company":"CALGARY RADIOPHARMACEUTICAL CENTRE / ALBERTA HEALTH SERVICES","date":"2025-03-22","status":"Marketed","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84585","refs":[]},{"name":"ATLANTISCAN","company":"NOVA SCOTIA HEALTH AUTHORITY","date":"2025-03-22","status":"Marketed","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92276","refs":[]},{"name":"CANTRACE","company":"IPET PHARMACEUTICALS INC.","date":"2025-03-22","status":"Cancelled Pre Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81461","refs":[]},{"name":"CARDIOLITE","company":"LANTHEUS MI CANADA INC","date":"2025-03-22","status":"Marketed","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81349","refs":["tc-99m-sestamibi"]},{"name":"CEA-SCAN","company":"IMMUNOMEDICS, INC.","date":"2025-03-22","status":"Cancelled Pre Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81559","refs":[]},{"name":"CERETEC","company":"GE HEALTHCARE CANADA INC","date":"2025-03-22","status":"Marketed","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81468","refs":["tc-99m-hmpao-brain"]},{"name":"CERETEC","company":"GE HEALTHCARE CANADA INC","date":"2026-08-14","status":"Marketed","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97437","refs":["tc-99m-hmpao-brain"]},{"name":"CHOLETEC","company":"BRACCO IMAGING CANADA","date":"2025-03-22","status":"Marketed","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81495","refs":[]},{"name":"CYANOCOBALAMIN (57CO) CAPSULES","company":"GE HEALTHCARE CANADA INC","date":"2025-03-22","status":"Cancelled Pre Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81462","refs":[]},{"name":"CYCLODX","company":"CIUSS DE L'ESTRIE - CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE","date":"2026-06-24","status":"Marketed","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95083","refs":[]},{"name":"DATSCAN","company":"GE HEALTHCARE CANADA INC","date":"2026-08-14","status":"Marketed","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95962","refs":["i-123-ioflupane"]},{"name":"DIISOPROPYL-IDA KIT FOR THE PREPARATION OF TECHNITIUM-99M DISOFENIN INJECTION","company":"EDMONTON RADIOPHARMACEUTICAL CENTRE (ALBERTA HEALTH SERVICES)","date":"2025-03-22","status":"Cancelled Pre Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97265","refs":[]},{"name":"DMSA","company":"GE HEALTHCARE CANADA INC","date":"2025-03-22","status":"Cancelled Pre Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81480","refs":[]},{"name":"DRAX EXAMETAZIME","company":"JUBILANT DRAXIMAGE INC. DBA JUBILANT RADIOPHARMA","date":"2026-04-01","status":"Marketed","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98574","refs":[]},{"name":"DRAXIMAGE DTPA","company":"JUBILANT DRAXIMAGE INC. DBA JUBILANT RADIOPHARMA","date":"2026-09-21","status":"Marketed","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81544","refs":[]},{"name":"DRAXIMAGE GLUCEPTATE","company":"JUBILANT DRAXIMAGE INC. DBA JUBILANT RADIOPHARMA","date":"2026-09-21","status":"Marketed","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82750","refs":[]},{"name":"DRAXIMAGE GLUCOHEPTONATE","company":"DRAXIMAGE A DIVISION OF DRAXIS SPECIALTY PHARMACEUTICALS INC","date":"2025-03-22","status":"Cancelled Pre Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81543","refs":[]},{"name":"DRAXIMAGE MAA","company":"JUBILANT DRAXIMAGE INC. DBA JUBILANT RADIOPHARMA","date":"2026-09-21","status":"Marketed","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81516","refs":["tc-99m-maa"]},{"name":"DRAXIMAGE MDP","company":"JUBILANT DRAXIMAGE INC. DBA JUBILANT RADIOPHARMA","date":"2026-09-21","status":"Marketed","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81515","refs":[]},{"name":"DRAXIMAGE MDP-25","company":"JUBILANT DRAXIMAGE INC. DBA JUBILANT RADIOPHARMA","date":"2026-09-21","status":"Marketed","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81492","refs":["tc-99m-mdp"]},{"name":"DRAXIMAGE SESTAMIBI","company":"JUBILANT DRAXIMAGE INC. DBA JUBILANT RADIOPHARMA","date":"2026-09-21","status":"Marketed","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81314","refs":["tc-99m-sestamibi"]},{"name":"DRAXIMAGE SODIUM IODIDE I131 CAPSULES, USP DIAGNOSTIC","company":"JUBILANT DRAXIMAGE INC. DBA JUBILANT RADIOPHARMA","date":"2026-09-15","status":"Marketed","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81547","refs":["nis-symporter"]},{"name":"DRAXIMAGE SODIUM IODIDE I131 CAPSULES, USP THERAPEUTIC","company":"JUBILANT DRAXIMAGE INC. DBA JUBILANT RADIOPHARMA","date":"2026-09-15","status":"Marketed","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81546","refs":["nis-symporter"]},{"name":"DRAXIMAGE SODIUM IODIDE I131 SOLUTION, USP DIAGNOSTIC","company":"JUBILANT DRAXIMAGE INC. DBA JUBILANT RADIOPHARMA","date":"2026-09-15","status":"Marketed","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81549","refs":["nis-symporter"]},{"name":"DRAXIMAGE SODIUM IODIDE I131 SOLUTION, USP THERAPEUTIC","company":"JUBILANT DRAXIMAGE INC. DBA JUBILANT RADIOPHARMA","date":"2026-09-15","status":"Marketed","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81548","refs":["nis-symporter"]},{"name":"DRAXIMAGE XENON XE 133","company":"JUBILANT DRAXIMAGE INC. DBA JUBILANT RADIOPHARMA","date":"2025-03-22","status":"Cancelled Post Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84521","refs":[]},{"name":"DRAXIMAGE XENON XE 133","company":"JUBILANT DRAXIMAGE INC. DBA JUBILANT RADIOPHARMA","date":"2025-03-22","status":"Cancelled Post Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84522","refs":[]},{"name":"FLUDEOXYGLUCOSE (18F) INJECTION","company":"SHARED HEALTH","date":"2025-04-25","status":"Marketed","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89749","refs":[]},{"name":"FLUDEOXYGLUCOSE (18F) INJECTION","company":"BC CANCER, PART OF THE PROVINCIAL HEALTH SERVICES AUTHORITY","date":"2025-03-22","status":"Marketed","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91763","refs":[]},{"name":"FLUDEOXYGLUCOSE (F-18)","company":"LAWSON HEALTH RESEARCH INSTITUTE","date":"2026-09-15","status":"Marketed","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95011","refs":[]},{"name":"FLUDEOXYGLUCOSE [F-18] FDG INJECTION","company":"THUNDER BAY REGIONAL HEALTH SCIENCES CENTRE","date":"2026-08-13","status":"Marketed","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95555","refs":[]},{"name":"FLUDEOXYGLUCOSE [F-18] FDG INJECTION","company":"THUNDER BAY REGIONAL HEALTH SCIENCES CENTRE","date":"2026-09-21","status":"Approved","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95556","refs":[]},{"name":"FLUDEOXYGLUCOSE F18 INJECTION","company":"MONTREAL NEUROLOGICAL INSTITUTE","date":"2025-03-22","status":"Cancelled Pre Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95873","refs":[]},{"name":"FLUGLUCOSCAN","company":"ALBERTA HEALTH SERVICES","date":"2025-03-22","status":"Marketed","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81315","refs":[]},{"name":"FLUOROHMET (CITRATE)","company":"UNIVERSITY OF OTTAWA HEART INSTITUTE - NATIONAL CARDIAC PET CENTRE","date":"2026-02-03","status":"Dormant","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84645","refs":[]},{"name":"FLUOROHMET (PHOSPHATE)","company":"UNIVERSITY OF OTTAWA HEART INSTITUTE - NATIONAL CARDIAC PET CENTRE","date":"2026-02-03","status":"Dormant","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97679","refs":[]},{"name":"GALLI EO","company":"IRE ELIT S.A.","date":"2025-03-22","status":"Marketed","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98280","refs":[]},{"name":"GALLIAPHARM","company":"ECKERT & ZIEGLER RADIOPHARMA GMBH","date":"2026-09-09","status":"Marketed","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99306","refs":["ge68-ga68-generators"]},{"name":"GALLIUM","company":"LANTHEUS MI CANADA INC","date":"2025-03-22","status":"Cancelled Post Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81316","refs":[]},{"name":"GALLIUM (GA67) CITRATE INJECTION","company":"CURIUM CANADA INC","date":"2025-03-22","status":"Marketed","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81328","refs":[]},{"name":"GALLIUM CITRATE GA 67 INJECTION","company":"BRISTOL-MYERS SQUIBB CANADA","date":"2025-03-22","status":"Cancelled Pre Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81552","refs":["ga-67-citrate"]},{"name":"GLUCOVISION (CITRATE)","company":"CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION","date":"2026-08-19","status":"Cancelled Post Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81441","refs":[]},{"name":"GLUCOVISION (CITRATE)","company":"CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION","date":"2026-08-19","status":"Cancelled Post Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97682","refs":[]},{"name":"GLUCOVISION (PHOSPHATE)","company":"CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION","date":"2026-08-19","status":"Cancelled Post Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97683","refs":[]},{"name":"GLUCOVISION (PHOSPHATE)","company":"CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION","date":"2026-08-19","status":"Cancelled Post Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97684","refs":[]},{"name":"GLUDEF","company":"ISOLOGIC INNOVATIVE RADIOPHARMACEUTICALS LTD.","date":"2026-09-15","status":"Cancelled Pre Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81879","refs":[]},{"name":"GLUDEF","company":"ISOLOGIC INNOVATIVE RADIOPHARMACEUTICALS LTD.","date":"2026-09-15","status":"Cancelled Pre Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81880","refs":[]},{"name":"HEPATATE","company":"MEDIAM","date":"2025-03-22","status":"Cancelled Pre Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81481","refs":[]},{"name":"HICON","company":"JUBILANT DRAXIMAGE INC. DBA JUBILANT RADIOPHARMA","date":"2026-09-21","status":"Dormant","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81336","refs":[]},{"name":"HICON","company":"JUBILANT DRAXIMAGE INC. DBA JUBILANT RADIOPHARMA","date":"2026-09-21","status":"Dormant","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97278","refs":[]},{"name":"HICON","company":"JUBILANT DRAXIMAGE INC. DBA JUBILANT RADIOPHARMA","date":"2026-09-21","status":"Dormant","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97279","refs":[]},{"name":"HIGH PURITY INDIUM CHLORIDE IN 111 STERILE SOLUTION","company":"CURIUM CANADA INC","date":"2025-03-22","status":"Dormant","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81520","refs":[]},{"name":"ILLUCCIX","company":"TELIX PHARMACEUTICALS (US), INC.","date":"2026-08-13","status":"Marketed","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102092","refs":["ga68-psma-11","illuccix"]},{"name":"INDIUM (111IN) OXINE SOLUTION","company":"GE HEALTHCARE CANADA INC","date":"2025-03-22","status":"Marketed","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81467","refs":["in-111"]},{"name":"INDIUM DTPA IN 111","company":"GE HEALTHCARE CANADA INC","date":"2025-03-22","status":"Marketed","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81479","refs":[]},{"name":"INDIUM IN-111 CHLORIDE STERILE SOLUTION","company":"GE HEALTHCARE CANADA INC","date":"2025-03-22","status":"Cancelled Pre Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81477","refs":[]},{"name":"INDIUM IN-111 CHLORIDE STERILE SOLUTION","company":"GE HEALTHCARE CANADA INC","date":"2025-03-22","status":"Cancelled Pre Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81478","refs":[]},{"name":"IODINE-123 META IODOBENZYLGUANIDINE","company":"EDMONTON RADIOPHARMACEUTICAL CENTRE (ALBERTA HEALTH SERVICES)","date":"2025-03-22","status":"Cancelled Pre Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83478","refs":["i-123"]},{"name":"IODINE-131 META IODOBENZYLGUANIDINE","company":"EDMONTON RADIOPHARMACEUTICAL CENTRE (ALBERTA HEALTH SERVICES)","date":"2025-03-22","status":"Cancelled Pre Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83480","refs":["i-131"]},{"name":"ISOJEX SYRINGES I 125","company":"TYCO HEALTHCARE","date":"2025-03-22","status":"Cancelled Pre Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81521","refs":[]},{"name":"KIT FOR THE PREPARATION OF TECHNETIUM (99MTC) PYROPHOSPHATE INJECTION","company":"ISOLOGIC INNOVATIVE RADIOPHARMACEUTICALS LTD.","date":"2026-06-09","status":"Dormant","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100307","refs":["tc-99m"]},{"name":"KIT FOR THE PREPARATION OF TECHNETIUM TC 99M SESTAMIBI INJECTION","company":"CURIUM CANADA INC","date":"2025-03-22","status":"Marketed","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81550","refs":["tc-99m-sestamibi"]},{"name":"LEUKOSCAN","company":"IMMUNOMEDICS, INC.","date":"2025-03-22","status":"Cancelled Pre Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81494","refs":[]},{"name":"LOCAMETZ","company":"NOVARTIS PHARMACEUTICALS CANADA INC","date":"2025-07-29","status":"Marketed","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102582","refs":["ga68-psma-11","locametz"]},{"name":"LUTATHERA","company":"NOVARTIS PHARMACEUTICALS CANADA INC","date":"2026-08-10","status":"Marketed","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97485","refs":["lutathera"]},{"name":"MACROTEC","company":"BRACCO IMAGING CANADA","date":"2025-03-22","status":"Cancelled Pre Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82752","refs":[]},{"name":"MDP MULTIDOSE UTILIPAK","company":"GE HEALTHCARE CANADA INC","date":"2025-03-22","status":"Cancelled Pre Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81474","refs":[]},{"name":"MDP-10","company":"EDMONTON RADIOPHARMACEUTICAL CENTRE (ALBERTA HEALTH SERVICES)","date":"2025-03-22","status":"Cancelled Pre Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97266","refs":[]},{"name":"MDP-21","company":"EDMONTON RADIOPHARMACEUTICAL CENTRE (ALBERTA HEALTH SERVICES)","date":"2025-03-22","status":"Cancelled Pre Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97277","refs":[]},{"name":"MDP-BRACCO","company":"BRACCO IMAGING CANADA","date":"2025-03-22","status":"Cancelled Pre Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81556","refs":[]},{"name":"METASTRON","company":"GE HEALTHCARE CANADA INC","date":"2025-03-22","status":"Cancelled Pre Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81469","refs":["sr-89-chloride"]},{"name":"MIRALUMA","company":"LANTHEUS MI CANADA INC","date":"2026-06-17","status":"Cancelled Pre Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81342","refs":["tc-99m-sestamibi"]},{"name":"MYOVIEW","company":"GE HEALTHCARE CANADA INC","date":"2025-03-22","status":"Marketed","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81439","refs":["tc-99m-tetrofosmin"]},{"name":"MYOVIEW 30ML","company":"GE HEALTHCARE CANADA INC","date":"2025-03-22","status":"Marketed","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90686","refs":["tc-99m-tetrofosmin"]},{"name":"NAF PLUS","company":"ISOLOGIC INNOVATIVE RADIOPHARMACEUTICALS LTD.","date":"2025-03-22","status":"Marketed","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88689","refs":[]},{"name":"NETSPOT","company":"NOVARTIS PHARMACEUTICALS CANADA INC","date":"2025-03-22","status":"Marketed","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98007","refs":["ga68-dotatate"]},{"name":"NETVISION","company":"UNIVERSITY HEALTH NETWORK","date":"2026-02-03","status":"Dormant","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101454","refs":[]},{"name":"NEURACEQ","company":"ISOLOGIC INNOVATIVE RADIOPHARMACEUTICALS LTD.","date":"2025-03-22","status":"Marketed","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94968","refs":["f-18-florbetaben"]},{"name":"NEUROLITE","company":"LANTHEUS MI CANADA INC","date":"2025-03-22","status":"Marketed","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81334","refs":[]},{"name":"OCTREOSCAN","company":"CURIUM CANADA INC","date":"2026-01-13","status":"Marketed","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81497","refs":["in-111-pentetreotide"]},{"name":"ONCOSCINT CR/OV","company":"HOSPIRA HEALTHCARE ULC","date":"2025-03-22","status":"Cancelled Pre Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81433","refs":[]},{"name":"OSTEOVISION","company":"CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION","date":"2025-03-22","status":"Dormant","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94988","refs":[]},{"name":"PENTETATE KIT FOR THE PREPARATION OF TECHNETIUM-PPM PENTETATE","company":"EDMONTON RADIOPHARMACEUTICAL CENTRE (ALBERTA HEALTH SERVICES)","date":"2025-03-22","status":"Cancelled Pre Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97267","refs":[]},{"name":"PHOSPHOCOL P32","company":"TYCO HEALTHCARE","date":"2026-06-17","status":"Cancelled Pre Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81501","refs":[]},{"name":"PHOSPHOTEC","company":"BRACCO IMAGING CANADA","date":"2025-03-22","status":"Cancelled Pre Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82751","refs":[]},{"name":"PLUVICTO","company":"NOVARTIS PHARMACEUTICALS CANADA INC","date":"2026-08-10","status":"Marketed","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101939","refs":["pluvicto"]},{"name":"PROSTALUMIN","company":"CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION","date":"2026-10-01","status":"Approved","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=107378","refs":["psma-1007-f18"]},{"name":"PROSTASCINT","company":"EUSA PHARMA INC","date":"2025-03-22","status":"Cancelled Pre Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81545","refs":[]},{"name":"PYTEST","company":"HALYARD HEALTH, INC","date":"2025-03-22","status":"Cancelled Pre Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94093","refs":[]},{"name":"QUADRAMET","company":"SUPERNA LIFE SCIENCES INCORPORATED","date":"2026-06-23","status":"Cancelled Pre Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81575","refs":["samarium-153-lexidronam"]},{"name":"RUBY-FILL","company":"JUBILANT DRAXIMAGE INC. DBA JUBILANT RADIOPHARMA","date":"2025-03-22","status":"Marketed","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85949","refs":["sr82-rb82-generators"]},{"name":"SEHCAT","company":"GE HEALTHCARE CANADA INC","date":"2026-04-29","status":"Cancelled Post Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81473","refs":[]},{"name":"SODIUM IODIDE (131I) SOLUTION","company":"ISOLOGIC INNOVATIVE RADIOPHARMACEUTICALS LTD.","date":"2025-03-22","status":"Marketed","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92430","refs":["nis-symporter","i-131"]},{"name":"SODIUM IODIDE I 131 ORAL SOLUTION","company":"MALLINCKRODT CANADA ULC","date":"2026-06-16","status":"Cancelled Post Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81540","refs":["nis-symporter"]},{"name":"SODIUM IODIDE I 131 ORAL SOLUTION","company":"MALLINCKRODT RP CANADA INC","date":"2025-03-22","status":"Cancelled Post Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81541","refs":["nis-symporter"]},{"name":"SODIUM IODIDE I 131 ORAL SOLUTION","company":"MALLINCKRODT RP CANADA INC","date":"2025-03-22","status":"Cancelled Post Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81542","refs":["nis-symporter"]},{"name":"SODIUM IODIDE I-123 CAPSULES","company":"GE HEALTHCARE CANADA INC","date":"2025-03-22","status":"Cancelled Pre Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81463","refs":["nis-symporter"]},{"name":"SODIUM IODIDE I-123 CAPSULES","company":"GE HEALTHCARE CANADA INC","date":"2025-03-22","status":"Cancelled Pre Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81464","refs":["nis-symporter"]},{"name":"SODIUM IODIDE I-123 CAPSULES","company":"MALLINCKRODT CANADA ULC","date":"2026-06-18","status":"Cancelled Pre Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88263","refs":["nis-symporter"]},{"name":"SODIUM IODIDE I-123 ORAL SOLUTION","company":"BWXT MEDICAL LTD.","date":"2025-03-22","status":"Marketed","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96912","refs":["nis-symporter"]},{"name":"SODIUM IODIDE I-131 CAPSULES","company":"MALLINCKRODT RP CANADA INC","date":"2025-03-22","status":"Cancelled Post Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81522","refs":["radioactive-iodine","nis-symporter","i-131"]},{"name":"SODIUM IODIDE I-131 CAPSULES","company":"MALLINCKRODT RP CANADA INC","date":"2025-03-22","status":"Cancelled Post Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81523","refs":["radioactive-iodine","nis-symporter","i-131"]},{"name":"SODIUM IODIDE I-131 CAPSULES","company":"MALLINCKRODT RP CANADA INC","date":"2025-03-22","status":"Cancelled Post Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81524","refs":["radioactive-iodine","nis-symporter","i-131"]},{"name":"SODIUM IODIDE I-131 CAPSULES","company":"MALLINCKRODT RP CANADA INC","date":"2025-03-22","status":"Cancelled Post Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81525","refs":["radioactive-iodine","nis-symporter","i-131"]},{"name":"SODIUM IODIDE I-131 CAPSULES","company":"MALLINCKRODT RP CANADA INC","date":"2025-03-22","status":"Cancelled Post Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81526","refs":["radioactive-iodine","nis-symporter","i-131"]},{"name":"SODIUM IODIDE I-131 CAPSULES","company":"MALLINCKRODT RP CANADA INC","date":"2025-03-22","status":"Cancelled Post Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81527","refs":["radioactive-iodine","nis-symporter","i-131"]},{"name":"SODIUM IODIDE I-131 CAPSULES","company":"MALLINCKRODT RP CANADA INC","date":"2025-03-22","status":"Cancelled Post Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81528","refs":["radioactive-iodine","nis-symporter","i-131"]},{"name":"SODIUM IODIDE I-131 CAPSULES","company":"MALLINCKRODT RP CANADA INC","date":"2025-03-22","status":"Cancelled Post Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81529","refs":["radioactive-iodine","nis-symporter","i-131"]},{"name":"SODIUM IODIDE I-131 CAPSULES","company":"MALLINCKRODT RP CANADA INC","date":"2025-03-22","status":"Cancelled Post Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81530","refs":["radioactive-iodine","nis-symporter","i-131"]},{"name":"SODIUM IODIDE I-131 CAPSULES","company":"MALLINCKRODT RP CANADA INC","date":"2025-03-22","status":"Cancelled Post Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81531","refs":["radioactive-iodine","nis-symporter","i-131"]},{"name":"SODIUM IODIDE I-131 CAPSULES","company":"MALLINCKRODT RP CANADA INC","date":"2025-03-22","status":"Cancelled Post Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81532","refs":["radioactive-iodine","nis-symporter","i-131"]},{"name":"SODIUM IODIDE I-131 CAPSULES","company":"MALLINCKRODT RP CANADA INC","date":"2025-03-22","status":"Cancelled Post Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81533","refs":["radioactive-iodine","nis-symporter","i-131"]},{"name":"SODIUM IODIDE I-131 CAPSULES","company":"MALLINCKRODT RP CANADA INC","date":"2025-03-22","status":"Cancelled Post Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81534","refs":["radioactive-iodine","nis-symporter","i-131"]},{"name":"SODIUM IODIDE I-131 CAPSULES","company":"MALLINCKRODT RP CANADA INC","date":"2025-03-22","status":"Cancelled Post Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81535","refs":["radioactive-iodine","nis-symporter","i-131"]},{"name":"SODIUM IODIDE I-131 CAPSULES","company":"MALLINCKRODT RP CANADA INC","date":"2025-03-22","status":"Cancelled Post Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81536","refs":["radioactive-iodine","nis-symporter","i-131"]},{"name":"SODIUM IODIDE I-131 CAPSULES","company":"MALLINCKRODT RP CANADA INC","date":"2025-03-22","status":"Cancelled Post Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81537","refs":["radioactive-iodine","nis-symporter","i-131"]},{"name":"SODIUM IODIDE I-131 CAPSULES","company":"MALLINCKRODT RP CANADA INC","date":"2025-03-22","status":"Cancelled Post Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81538","refs":["radioactive-iodine","nis-symporter","i-131"]},{"name":"SODIUM IODIDE I-131 CAPSULES","company":"MALLINCKRODT RP CANADA INC","date":"2025-03-22","status":"Cancelled Post Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81539","refs":["radioactive-iodine","nis-symporter","i-131"]},{"name":"SODIUM IODIDE I-131 SOLUTION U.S.P (INJECTION) DIAGNOSTIC","company":"EDMONTON RADIOPHARMACEUTICAL CENTRE (ALBERTA HEALTH SERVICES)","date":"2025-03-22","status":"Cancelled Pre Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97307","refs":["radioactive-iodine","nis-symporter","i-131"]},{"name":"SODIUM IODIDE I-131 SOLUTION U.S.P (INJECTION) THERAPEUTIC","company":"EDMONTON RADIOPHARMACEUTICAL CENTRE (ALBERTA HEALTH SERVICES)","date":"2025-03-22","status":"Cancelled Pre Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97308","refs":["radioactive-iodine","nis-symporter","i-131"]},{"name":"SODIUM IODIDE I-131 SOLUTION U.S.P (ORAL) DIAGNOSTIC","company":"EDMONTON RADIOPHARMACEUTICAL CENTRE (ALBERTA HEALTH SERVICES)","date":"2025-03-22","status":"Cancelled Pre Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97309","refs":["radioactive-iodine","nis-symporter","i-131"]},{"name":"SODIUM IODIDE I-131 SOLUTION U.S.P (ORAL) THERAPEUTIC","company":"EDMONTON RADIOPHARMACEUTICAL CENTRE (ALBERTA HEALTH SERVICES)","date":"2025-03-22","status":"Cancelled Pre Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97310","refs":["radioactive-iodine","nis-symporter","i-131"]},{"name":"SODIUM PERTECHNETATE 99MTC INJECTION","company":"BC CANCER, PART OF THE PROVINCIAL HEALTH SERVICES AUTHORITY","date":"2025-03-22","status":"Approved","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99762","refs":["nis-symporter","tc-99m"]},{"name":"STANNOUS AGENT","company":"MEDIAM","date":"2025-03-22","status":"Cancelled (Unreturned Annual)","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81458","refs":[]},{"name":"STANNOUS DISIDA KIT","company":"CALGARY RADIOPHARMACEUTICAL CENTRE / ALBERTA HEALTH SERVICES","date":"2025-03-22","status":"Marketed","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97623","refs":[]},{"name":"STANNOUS MAA KIT","company":"CALGARY RADIOPHARMACEUTICAL CENTRE / ALBERTA HEALTH SERVICES","date":"2026-09-21","status":"Marketed","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83145","refs":[]},{"name":"STANNOUS MDP KIT","company":"CALGARY RADIOPHARMACEUTICAL CENTRE / ALBERTA HEALTH SERVICES","date":"2026-09-17","status":"Marketed","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97605","refs":[]},{"name":"STANNOUS PYP KIT","company":"CALGARY RADIOPHARMACEUTICAL CENTRE / ALBERTA HEALTH SERVICES","date":"2025-03-22","status":"Marketed","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97624","refs":[]},{"name":"STANNOUS PYROPHOSPHATE","company":"EDMONTON RADIOPHARMACEUTICAL CENTRE (ALBERTA HEALTH SERVICES)","date":"2026-06-17","status":"Cancelled Pre Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83131","refs":[]},{"name":"SULFUR COLLOID KIT","company":"CALGARY RADIOPHARMACEUTICAL CENTRE / ALBERTA HEALTH SERVICES","date":"2025-03-22","status":"Marketed","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97628","refs":[]},{"name":"TECHNELITE","company":"LANTHEUS MI CANADA INC","date":"2026-09-15","status":"Marketed","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81407","refs":[]},{"name":"TECHNESCAN HDP KIT","company":"TYCO HEALTHCARE","date":"2025-03-22","status":"Cancelled Pre Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81519","refs":[]},{"name":"TECHNESCAN MAG3","company":"CURIUM CANADA INC","date":"2025-03-22","status":"Marketed","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81499","refs":[]},{"name":"TECHNESCAN PYP","company":"MALLINCKRODT CANADA ULC","date":"2026-06-18","status":"Cancelled Pre Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81500","refs":["tc-99m-pyrophosphate"]},{"name":"TECHNETIUM TC 99M TSC","company":"GE HEALTHCARE CANADA INC","date":"2025-03-22","status":"Marketed","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81460","refs":[]},{"name":"THALLIUM","company":"LANTHEUS MI CANADA INC","date":"2025-03-22","status":"Cancelled Post Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81344","refs":[]},{"name":"THALLIUM","company":"LANTHEUS MI CANADA INC","date":"2026-06-17","status":"Cancelled Pre Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81346","refs":[]},{"name":"THALLIUM, THALLOUS CHLORIDE TI201","company":"BRISTOL-MYERS SQUIBB CANADA","date":"2025-03-22","status":"Cancelled Pre Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81555","refs":[]},{"name":"THALLOUS CHLORIDE TI 201 INJECTION","company":"GE HEALTHCARE CANADA INC","date":"2025-03-22","status":"Cancelled Post Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97615","refs":[]},{"name":"THALLOUS CHLORIDE TI-201 INJECTION","company":"CURIUM CANADA INC","date":"2025-06-23","status":"Dormant","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81459","refs":[]},{"name":"ULTRA-TECHNEKOW DTE","company":"MALLINCKRODT CANADA ULC","date":"2026-06-18","status":"Cancelled Pre Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81509","refs":[]},{"name":"ULTRA-TECHNEKOW DTE","company":"MALLINCKRODT CANADA ULC","date":"2026-06-18","status":"Cancelled Pre Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81510","refs":[]},{"name":"ULTRA-TECHNEKOW DTE","company":"MALLINCKRODT CANADA ULC","date":"2026-06-18","status":"Cancelled Pre Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81511","refs":[]},{"name":"ULTRA-TECHNEKOW DTE","company":"MALLINCKRODT CANADA ULC","date":"2026-06-18","status":"Cancelled Pre Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81512","refs":[]},{"name":"ULTRA-TECHNEKOW DTE","company":"MALLINCKRODT CANADA ULC","date":"2026-06-18","status":"Cancelled Pre Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81513","refs":[]},{"name":"ULTRA-TECHNEKOW DTE","company":"MALLINCKRODT CANADA ULC","date":"2026-06-18","status":"Cancelled Pre Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81514","refs":[]},{"name":"ULTRA-TECHNEKOW V4","company":"CURIUM CANADA INC","date":"2025-12-22","status":"Marketed","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92599","refs":[]},{"name":"ULTRATAG RBC","company":"CURIUM CANADA INC","date":"2025-03-22","status":"Marketed","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81508","refs":[]},{"name":"XENON","company":"LANTHEUS MI CANADA INC","date":"2026-06-17","status":"Cancelled Pre Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81338","refs":[]},{"name":"XENON","company":"LANTHEUS MI CANADA INC","date":"2026-06-17","status":"Cancelled Pre Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81339","refs":[]},{"name":"XENON XE-133 GAS","company":"BRISTOL-MYERS SQUIBB CANADA","date":"2025-03-22","status":"Cancelled Pre Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81438","refs":[]},{"name":"XOFIGO","company":"BAYER INC","date":"2025-03-22","status":"Marketed","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90297","refs":["radium-223"]},{"name":"YTTRIGA","company":"ECKERT & ZIEGLER RADIOPHARMA GMBH","date":"2025-06-25","status":"Dormant","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95954","refs":[]},{"name":"YTTRIUM-90 CHLORIDE STERILE SOLUTION","company":"MDS NORDION, A DIVISION OF MDS (CANADA) INC.","date":"2025-03-22","status":"Cancelled Pre Market","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81482","refs":["y-90"]},{"name":"ZEVALIN","company":"AURO PHARMA INC","date":"2025-03-22","status":"Approved","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81418","refs":["ibritumomab-tiuxetan"]}]},"switzerland":{"source":"https://www.swissmedic.ch/dam/swissmedic/en/dokumente/internetlisten/zugelassene_arzneimittel_ham_ind.xlsx.download.xlsx/Zugelassene_Arzneimittel_HAM.xlsx","asOf":"30.09.2026","total":58,"rows":[{"id":"2052-08-27","name":"18F-FDG-FR, Injektionslösung","company":"Posimed Radiopharm AG","date":"2002-02-04","lang":"de-fr","refs":["f-18-fdg-brain"]},{"id":"2071-04-05","name":"18F-Fluorocholine ZRP, Injektionslösung zur i.v. Applikation","company":"Universitätsspital Zürich","date":"2012-10-02","lang":"de-fr","refs":[]},{"id":"2073-04-07","name":"18F-Fluoroethyltyrosine ZRP 0.05-3.5 GBq/ml, Injektionslösung zur IV Applikation","company":"Universitätsspital Zürich","date":"2014-07-25","lang":"de-fr","refs":[]},{"id":"2078-07-16","name":"18F-Fluoroglukose ZRP 0.5 - 5 GBq/ml, Injektionslösung zur i.v. Applikation","company":"Universitätsspital Zürich","date":"2014-12-17","lang":"de-fr","refs":[]},{"id":"2084-07-16","name":"18F-PSMA-1007 ZRP ≥ 40 MBq / mL, Injektionslösung","company":"Universitätsspital Zürich","date":"2024-06-11","lang":"de-fr","refs":["psma"]},{"id":"2080-02-18","name":"AAACholine 222 MBq/ml, Injektionslösung","company":"Siemens Healthineers Radiopharma CH GmbH","date":"2016-09-21","lang":"de-fr","refs":[]},{"id":"2043-11-03","name":"AdreView, Iobenguane (I-123) Injection","company":"medeo AG","date":"1994-12-29","lang":"de-fr","refs":["i-123-mibg-cardiac","i-123-mibg"]},{"id":"2072-03-14","name":"Amyvid 1900 MBq/ml, solution pour injection","company":"Eli Lilly (Suisse) SA","date":"2014-01-09","lang":"de-fr","refs":["f-18-florbetapir"]},{"id":"2072-03-14","name":"Amyvid 800 MBq/ml, solution pour injection","company":"Eli Lilly (Suisse) SA","date":"2014-01-09","lang":"de-fr","refs":["f-18-florbetapir"]},{"id":"2070-08-27","name":"Cardiogen-82, generatore di radionuclidi","company":"Bracco Suisse SA","date":"2013-05-17","lang":"de-fr","refs":["rb-82-chloride","sr82-rb82-generators"]},{"id":"2041-07-21","name":"Citrate d'Yttrium (90Y)-YMM-1, Suspension zur Injektion","company":"b.e.imaging.ag","date":"1999-07-20","lang":"de-fr","refs":[]},{"id":"2052-07-17","name":"DaTSCAN TM 123 I-Ioflupane (INN), Injektionslösung","company":"GE Healthcare AG","date":"2001-06-25","lang":"de-fr","refs":["i-123-ioflupane"]},{"id":"2080-05-23","name":"Dopaview 222 MBq/ml, Injektionslösung","company":"Siemens Healthineers Radiopharma CH GmbH","date":"2016-09-21","lang":"de-fr","refs":[]},{"id":"2068-07-02","name":"Flu-SWAN, Injektionslösung","company":"SWAN Isotopen AG SWAN Haus, Inselspital","date":"2010-08-04","lang":"de-fr","refs":[]},{"id":"2092-08-21","name":"Galli Ad 0.74 – 3.70 GBq, Radionuklidgenerator","company":"b.e.imaging.ag","date":"2026-08-25","lang":"de-fr","refs":[]},{"id":"2056-08-24","name":"Glupet, solution injectable","company":"Les hôpitaux universitaires de Genève","date":"2005-12-08","lang":"de-fr","refs":[]},{"id":"2056-11-05","name":"Gluscan, Injektionslösung in einem Mehrdosenbehältnis","company":"Siemens Healthineers Radiopharma CH GmbH","date":"2004-12-23","lang":"de-fr","refs":[]},{"id":"2056-01-05","name":"Indium (In-111) Chloride Solution Curium 370 MBq/ml, Lösung zur Radiomarkierung","company":"b.e.imaging.ag","date":"2004-04-16","lang":"de-fr","refs":["curium"]},{"id":"2088-01-18","name":"Locametz 25 ug, Mehrfachdosis-Kit für ein radioaktives Arzneimittel","company":"Novartis Pharma Schweiz AG","date":"2023-03-03","lang":"de-fr","refs":["ga68-psma-11","locametz"]},{"id":"2091-01-13","name":"Lutathera 370 MBq/mL, Infusionslösung","company":"Novartis Pharma Schweiz AG","date":"2024-11-22","lang":"de-fr","refs":["lutathera"]},{"id":"2082-04-14","name":"Lutathera CA 370 MBq/ml, Infusionslösung","company":"Novartis Pharma Schweiz AG","date":"2019-06-25","lang":"de-fr","refs":["lutathera"]},{"id":"2057-10-27","name":"MAG-3 Kit, Markierungsbesteck","company":"medeo AG","date":"2006-08-22","lang":"de-fr","refs":[]},{"id":"2044-05-14","name":"MIBG (I-123) injection Curium, Injektionslösung","company":"b.e.imaging.ag","date":"1994-08-09","lang":"de-fr","refs":["curium"]},{"id":"2046-11-22","name":"Myoview, Markierungsbesteck","company":"GE Healthcare AG","date":"1999-06-03","lang":"de-fr","refs":["tc-99m-tetrofosmin"]},{"id":"2085-11-30","name":"NanoHSA-ROTOP 0.5 ,mg, Markierungsbesteck","company":"medeo AG","date":"2021-08-25","lang":"de-fr","refs":[]},{"id":"2067-09-08","name":"Natriumfluorid (18F) ZRP, Injektionslösung","company":"Universitätsspital Zürich","date":"2010-05-06","lang":"de-fr","refs":[]},{"id":"2043-12-08","name":"Natriumiodid (I-123), Diagnosekapseln","company":"medeo AG","date":"1995-05-08","lang":"de-fr","refs":[]},{"id":"2043-12-09","name":"Natriumiodid (I-123), Injektionslösung","company":"medeo AG","date":"1995-05-08","lang":"de-fr","refs":[]},{"id":"2082-05-15","name":"Netspot 40 mcg, Kit für ein radioaktives Arzneimittel","company":"Novartis Pharma Schweiz AG","date":"2018-10-26","lang":"de-fr","refs":["ga68-dotatate"]},{"id":"2081-04-09","name":"Neuraceq 300 MBq/ml, Injektionslösung","company":"SWAN Isotopen AG SWAN Haus, Inselspital","date":"2017-08-23","lang":"de-fr","refs":["f-18-florbetaben"]},{"id":"2080-02-02","name":"Pertector 2.3-57.1 GBq, Radionuklidgenerator","company":"medeo AG","date":"2016-01-14","lang":"de-fr","refs":[]},{"id":"2088-01-17","name":"Pluvicto 1000 MBq/ml, Injektions-/Infusionslösung","company":"Novartis Pharma Schweiz AG","date":"2023-02-24","lang":"de-fr","refs":["pluvicto"]},{"id":"2088-12-25","name":"Pluvicto CA 1000 MBq/ml, Injektions-/Infusionslösung","company":"Novartis Pharma Schweiz AG","date":"2023-02-24","lang":"de-fr","refs":["pluvicto"]},{"id":"2091-01-12","name":"Pylclari 1000 MBq/ml, Injektionslösung","company":"b.e.imaging.ag","date":"2025-04-25","lang":"de-fr","refs":[]},{"id":"2091-01-12","name":"Pylclari 1500 MBq/ml, Injektionslösung","company":"b.e.imaging.ag","date":"2025-04-25","lang":"de-fr","refs":[]},{"id":"2084-07-12","name":"Radelumin 200 - 4500 MBq/ml, Injektionslösung","company":"Posimed Radiopharm AG","date":"2024-06-11","lang":"de-fr","refs":[]},{"id":"2090-02-22","name":"RoTecPSMA 80 μg, Kit für ein radioaktives Arzneimittel","company":"medeo AG","date":"2025-08-08","lang":"de-fr","refs":[]},{"id":"2078-03-06","name":"Ruby-Fill (Rubidium Rb-82 Generator) 3.7 GBq, Generator","company":"medeo AG","date":"2015-12-18","lang":"de-fr","refs":["sr82-rb82-generators","rb-82-chloride"]},{"id":"2041-06-20","name":"Scintimun, Markierungsbesteck","company":"b.e.imaging.ag","date":"1992-10-30","lang":"de-fr","refs":[]},{"id":"2044-05-12","name":"Sodium iodide (I-123) injection Curium, Injektionslösung","company":"b.e.imaging.ag","date":"1994-08-09","lang":"de-fr","refs":["curium","nis-symporter"]},{"id":"2044-05-11","name":"Sodium iodide (I-131) capsule T Curium, Therapiekapseln","company":"b.e.imaging.ag","date":"1994-08-09","lang":"de-fr","refs":["curium","nis-symporter","i-131"]},{"id":"2061-09-13","name":"Stamicis, Markierungsbesteck","company":"b.e.imaging.ag","date":"2009-09-11","lang":"de-fr","refs":[]},{"id":"2087-10-18","name":"Striascan 74 MBq/ml, Injektionslösung","company":"b.e.imaging.ag","date":"2022-09-09","lang":"de-fr","refs":[]},{"id":"2080-12-07","name":"SWAN-Cholin 222 MBq/ml, Injektionslösung","company":"SWAN Isotopen AG SWAN Haus, Inselspital","date":"2016-10-21","lang":"de-fr","refs":[]},{"id":"2084-06-12","name":"SWAN-PSMA-1007 1 ml / 10 ml, Injektionslösung","company":"SWAN Isotopen AG SWAN Haus, Inselspital","date":"2024-06-11","lang":"de-fr","refs":["psma"]},{"id":"2021-11-21","name":"Teceos, Markierungsbesteck","company":"b.e.imaging.ag","date":"1984-02-20","lang":"de-fr","refs":[]},{"id":"2051-10-20","name":"TechneScan DMSA, Markierungsbesteck","company":"b.e.imaging.ag","date":"2001-07-25","lang":"de-fr","refs":[]},{"id":"2017-03-15","name":"TechneScan DTPA, Markierungsbesteck","company":"b.e.imaging.ag","date":"1984-05-14","lang":"de-fr","refs":[]},{"id":"2035-11-25","name":"TechneScan HDP, Markierungsbesteck","company":"b.e.imaging.ag","date":"1992-06-25","lang":"de-fr","refs":[]},{"id":"2036-05-01","name":"TechneScan MAG3, Tc-99m-Markierungsbesteck","company":"b.e.imaging.ag","date":"1989-05-25","lang":"de-fr","refs":["tc-99m"]},{"id":"2062-01-25","name":"TechneScan Sestamibi, Lyophilisat zur Markierung mit Tc-99m (Markierungsbesteck)","company":"b.e.imaging.ag","date":"2009-06-02","lang":"de-fr","refs":["tc-99m-sestamibi","tc-99m"]},{"id":"2082-03-05","name":"Tektrotyd, Markierungsbesteck","company":"medeo AG","date":"2018-04-25","lang":"de-fr","refs":[]},{"id":"2049-05-03","name":"Tetley Technegas, Generator","company":"medeo AG","date":"1998-02-18","lang":"de-fr","refs":["technegas"]},{"id":"2020-08-22","name":"Thallous chloride (TI-201) injection Curium, Injektionslösung","company":"b.e.imaging.ag","date":"1985-12-11","lang":"de-fr","refs":["curium"]},{"id":"2035-02-18","name":"UltratechneKow FM, Generator","company":"b.e.imaging.ag","date":"1990-06-12","lang":"de-fr","refs":[]},{"id":"2080-12-30","name":"Vizamyl 150MBq/ml, Injektionslösung","company":"GE Healthcare AG","date":"2017-04-12","lang":"de-fr","refs":["f-18-flutemetamol"]},{"id":"2071-10-01","name":"Xofigo 1100 kBq/ml Ra-223-Dichlorid, Injektionslösung","company":"Bayer (Schweiz) AG","date":"2014-08-29","lang":"de-fr","refs":["radium-223","ra-223"]},{"id":"2053-08-18","name":"Zevalin, Kit für die Herstellung eines Radiotherapeutikums","company":"Target BioScience AG","date":"2004-04-19","lang":"de-fr","refs":["ibritumomab-tiuxetan"]}],"note":"Product names are Swissmedic's own German and French listings and are not translated here; the class column 'Radiopharmazeutika' is the filter."},"china":{"source":"https://english.nmpa.gov.cn/news.html , https://english.nmpa.gov.cn/drugs.html","scanned":20,"latest":"2026-10-23","matches":[]},"korea":{"source":"https://www.mfds.go.kr/eng/brd/m_61/list.do","scanned":10,"matches":[]},"japan":{"source":"https://www.pmda.go.jp/files/000281190.pdf","bytes":3206009,"lastModified":"Mon, 22 Jun 2026 03:02:32 GMT","changed":false,"note":"PMDA publishes one cumulative English list of approved drugs (April 2004 onwards) as a PDF. There is no per-year English file and no PDF parser here, so a change in the file is a flag to re-read it, not an automatic corpus update."}},"errors":[],"euTrials":{"source":"https://euclinicaltrials.eu/ctis-public-api/search","terms":["radioligand","lutetium","actinium","radiopharmaceutical","PSMA"],"total":127,"byCountry":{"Belgium":21,"Germany":28,"France":46,"Spain":36,"Italy":36,"Czechia":9,"Denmark":6,"Sweden":17,"Netherlands":36,"Austria":11,"Poland":14,"Cyprus":2,"Finland":8,"Norway":4,"Lithuania":1,"Hungary":4,"Portugal":3,"Slovakia":4,"Ireland":2,"Greece":1,"Estonia":1},"items":[{"ctNumber":"2023-508709-26-00","title":"F-18 PSMA-11 PET for Imaging and Staging of Hepatocellular carcinoma with Evaluation of Survival","sponsor":"Universitair Ziekenhuis Gent","phase":"Therapeutic exploratory (Phase II)","countries":["Belgium"],"started":"31/07/2026","conditions":"Hepatocellular carcinoma","url":"https://euclinicaltrials.eu/ctis-public/view/2023-508709-26-00","terms":["PSMA"],"refs":["hcc","psma"]},{"ctNumber":"2025-521859-23-00","title":"A phase Ib/II open-label, multi-center study of the DNA protein kinase inhibitor AMO959 with lutetium (177Lu) vipivotide tetraxetan (AAA617) in combination with an androgen receptor pathway inhibitor (ARPI) in adult participants with PSMA-positive metastatic castration resistant prostate cancer (mCRPC)","sponsor":"Novartis Pharma AG","phase":"Phase I and Phase II (Integrated)- Other","countries":["Germany","France","Spain","Italy"],"started":"31/03/2026","conditions":"PSMA-positive mCRPC with prior exposure to at least one prior ARPI","url":"https://euclinicaltrials.eu/ctis-public/view/2025-521859-23-00","terms":["lutetium","PSMA"],"refs":["prostate","prostate-mcrpc","lu177-radioligand-therapy","lu-177","psma"]},{"ctNumber":"2023-507970-42-00","title":"PSMAddition: An International Prospective Open-label, Randomized, Phase III Study comparing 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)","sponsor":"Novartis Pharma AG","phase":"Therapeutic confirmatory (Phase III)","countries":["Czechia","Denmark","Spain","Germany","France","Sweden","Belgium","Netherlands","Austria","Poland"],"started":"31/03/2021","conditions":"PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC)","url":"https://euclinicaltrials.eu/ctis-public/view/2023-507970-42-00","terms":["radiopharmaceutical","PSMA"],"refs":["prostate-mhspc","prostate","pluvicto","lu177-radioligand-therapy","lu-177","psma"]},{"ctNumber":"2024-515821-27-00","title":"LAVA1207-001/LAVA1207-002 A Phase 1 and 2a open-label trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of LAVA-1207, a PSMA-targeting bispecific γδ-T cell engager, alone or with low dose interleukin-2 or Pembrolizumab, in patients with therapy refractory metastatic castration resistant prostate cancer","sponsor":"LAVA Therapeutics N.V.","phase":"Phase I and Phase II (Integrated)- Other","countries":["Spain","Netherlands"],"started":"30/11/2021","conditions":"Prostate Cancer, Prostate Cancer","url":"https://euclinicaltrials.eu/ctis-public/view/2024-515821-27-00","terms":["PSMA"],"refs":["prostate","pembrolizumab","psma"]},{"ctNumber":"2023-504917-54-00","title":"A randomized trial comparing conventional \"salvage\" radiotherapy and individualized PSMA-PET/CT targeted treatment in patients with biochemical recurrence after prostate cancer surgery","sponsor":"Karolinska University Hospital","phase":"Therapeutic confirmatory (Phase III)","countries":["Sweden"],"started":"30/10/2018","conditions":"Biochemical recurrence after prostate cancer surgery","url":"https://euclinicaltrials.eu/ctis-public/view/2023-504917-54-00","terms":["radiopharmaceutical","PSMA"],"refs":["prostate","psma"]},{"ctNumber":"2024-520105-39-00","title":"A dosimetry trial of uPAR targeted radioligand therapy in patients with glioblastoma","sponsor":"Curasight A/S","phase":"Human Pharmacology (Phase I)- Other","countries":["Denmark"],"started":"30/09/2026","conditions":"Glioblastoma","url":"https://euclinicaltrials.eu/ctis-public/view/2024-520105-39-00","terms":["radioligand"],"refs":["radioligand-therapy","glioblastoma","upar"]},{"ctNumber":"2024-510812-64-00","title":"A Prospective, Randomized, Controlled, Open-label, Multicenter Trial to Evaluate Efficacy, Safety and Patient-reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium (177Lu) Edotreotide compared to Best Standard of Care in Patients with Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin Receptor‑positive (SSTR+), Neuroendocrine Tumors of GastroEnteric or Pancreatic Origin","sponsor":"ITM Solucin GmbH","phase":"Therapeutic confirmatory (Phase III)","countries":["Netherlands","Spain","Italy","France","Germany"],"started":"30/09/2021","conditions":"Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin receptor-positive (SSTR+), Neuroendocrine Tumors of GastroEnteric or Pancreatic Origin (GEP-NET)","url":"https://euclinicaltrials.eu/ctis-public/view/2024-510812-64-00","terms":["lutetium"],"refs":["prrt","ga-68-dotatoc","lu177-radioligand-therapy","lu-177"]},{"ctNumber":"2024-511252-41-00","title":"ADOPT; Androgen Deprivation therapy for Oligo-recurrent Prostate cancer in addition to radioTherapy","sponsor":"Universitair Medisch Centrum Groningen","phase":"Therapeutic confirmatory (Phase III)","countries":["Netherlands"],"started":"30/07/2024","conditions":"Patients with biochemical recurrence after primary treatment of prostate cancer presenting with =<4 metastases","url":"https://euclinicaltrials.eu/ctis-public/view/2024-511252-41-00","terms":["PSMA"],"refs":["prostate"]},{"ctNumber":"2025-523273-41-00","title":"A Phase 1/2 dose escalation trial with administration schedule exploration evaluating single agent TD001, a PSMA-targeted antibody-drug conjugate, in patients with PSMA-expressing metastatic castration-resistant prostate cancer","sponsor":"T.O.A.D. Oncology S.A.","phase":"Phase I and Phase II (Integrated)- First administration to humans","countries":["Spain","France"],"started":"30/01/2026","conditions":"Metastatic castration-resistant prostate cancer","url":"https://euclinicaltrials.eu/ctis-public/view/2025-523273-41-00","terms":["PSMA"],"refs":["prostate-mcrpc","prostate","psma"]},{"ctNumber":"2024-516566-11-00","title":"Impact of microglial activation on synaptic density in Alzheimer’s disease","sponsor":"Groupe Hospitalier Universitaire Paris Psychiatrie Et Neuroscience","phase":"Therapeutic exploratory (Phase II)","countries":["France"],"started":"29/11/2024","conditions":"Alzeihmer disease","url":"https://euclinicaltrials.eu/ctis-public/view/2024-516566-11-00","terms":["radioligand"],"refs":[]},{"ctNumber":"2023-505655-43-00","title":"A Phase I, open-label, multi-center exploratory safety and efficacy study with PSMA, SSTR2 and GRPR targeted radioligand therapy in metastatic neuroendocrine prostate cancer","sponsor":"Novartis Pharma AG","phase":"Phase I and Phase II (Integrated)- First administration to humans","countries":["France","Germany","Italy","Spain"],"started":"29/07/2024","conditions":"Metastatic neuroendocrine prostate cancer","url":"https://euclinicaltrials.eu/ctis-public/view/2023-505655-43-00","terms":["radioligand","PSMA"],"refs":["radioligand-therapy","prostate","grpr","psma"]},{"ctNumber":"2023-507170-41-00","title":"A Phase I/IIa open-label, multi-center study to evaluate the safety, tolerability, whole-body distribution, radiation dosimetry and anti-tumor activity of [177Lu]-NeoB administered in patients with advanced solid tumors known to overexpress gastrin-releasing peptide receptor (GRPR).","sponsor":"Advanced Accelerator Applications International S.A.","phase":"Phase I and Phase II (Integrated)- First administration to humans","countries":["Spain","Netherlands","Austria","France"],"started":"29/07/2019","conditions":"Solid tumors known to overexpress GRPR and with [68Ga]-NeoB lesion uptake.","url":"https://euclinicaltrials.eu/ctis-public/view/2023-507170-41-00","terms":["radiopharmaceutical"],"refs":["lu177-radioligand-therapy","lu-177","grpr","ga-68"]},{"ctNumber":"2022-502703-30-00","title":"Continuing Somatostatin Analogues Upon progression in Neuroendocrine tumour pAtients (SAUNA trial)","sponsor":"Antwerp University Hospital","phase":"Therapeutic use (Phase IV)","countries":["Netherlands","Belgium"],"started":"28/06/2023","conditions":"neuroendocrine tumours","url":"https://euclinicaltrials.eu/ctis-public/view/2022-502703-30-00","terms":["lutetium"],"refs":["neuroendocrine"]},{"ctNumber":"2022-500570-33-00","title":"A Randomised, Open Label, Phase III, Multicenter, 2-arm study comparing 177Lu-PSMA-I&T versus Apalutamide/Enzalutamide/Abiraterone, in metastatic Hormon Sensitive Prostate Cancer Patients receiving castration treatment","sponsor":"Region Västerbotten, Umea University","phase":"Therapeutic confirmatory (Phase III)","countries":["Sweden"],"started":"28/02/2024","conditions":"Prostate cancer","url":"https://euclinicaltrials.eu/ctis-public/view/2022-500570-33-00","terms":["lutetium","PSMA"],"refs":["prostate","lu177-psma-it","lu-177-pnt2002","enzalutamide","lu177-radioligand-therapy","lu-177","psma"]},{"ctNumber":"2024-515604-39-00","title":"SPLASH: Study Evaluating Metastatic Castrate Resistant Prostate Cancer Treatment Using 177Lu-PNT2002 PSMA Therapy After Second-line Hormonal Treatment","sponsor":"Point Biopharma Inc.","phase":"Therapeutic confirmatory (Phase III)","countries":["Sweden","Netherlands","France"],"started":"28/01/2022","conditions":"Metastatic castration-resistant prostate cancer (mCRPC)","url":"https://euclinicaltrials.eu/ctis-public/view/2024-515604-39-00","terms":["lutetium","PSMA"],"refs":["prostate-mcrpc","prostate","lu-177-pnt2002","lu177-psma-it","lu177-radioligand-therapy","lu-177","psma"]},{"ctNumber":"2023-509881-39-00","title":"Lutetium-177-PSMA in Oligo-metastatic Hormone Sensitive Prostate Cancer.","sponsor":"Stichting Radboud University Medical Center","phase":"Therapeutic exploratory (Phase II)","countries":["Cyprus","Netherlands"],"started":"27/07/2020","conditions":"prostate cancer","url":"https://euclinicaltrials.eu/ctis-public/view/2023-509881-39-00","terms":["lutetium","PSMA"],"refs":["prostate","lu177-radioligand-therapy","lu-177","psma"]},{"ctNumber":"2024-519347-15-00","title":"A phase II randomized trial of Lu-PSMA and Stereotactic Radiotherapy versus Radiotherapy alone for oligometastatic prostate cancer (LUST)","sponsor":"Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.","phase":"Therapeutic exploratory (Phase II)","countries":["Italy"],"started":"27/06/2023","conditions":"Oligometastatic prostate carcinoma","url":"https://euclinicaltrials.eu/ctis-public/view/2024-519347-15-00","terms":["PSMA"],"refs":["prostate","psma"]},{"ctNumber":"2023-504458-36-02","title":"Evaluation of the expression of somatostatin receptors in DOTATOC-68Ga PET scans in patients followed for metastatic breast cancer","sponsor":"Centre Hospitalier Universitaire Grenoble Alpes","phase":"Therapeutic exploratory (Phase II)","countries":["France"],"started":"26/09/2024","conditions":"Breast Cancer","url":"https://euclinicaltrials.eu/ctis-public/view/2023-504458-36-02","terms":["radiopharmaceutical"],"refs":["ga-68"]},{"ctNumber":"2024-514386-19-00","title":"A phase I study of neoadjuvant treatment with 177-Lutetium-PSMA-617 with Ipilimumab in subjects with very high-risk prostate cancer who are candidates for radical prostatectomy (NEPI Trial)","sponsor":"Universitaetsklinikum Essen AöR","phase":"Human Pharmacology (Phase I)- Other","countries":["Germany"],"started":"25/08/2025","conditions":"Patients with very high-risk prostate cancer (as defined by a total Gleason-Score ≥4+4 [ISUP-GG 4+5] and clinical stage cT3 (digital rectal examinations or imaging based) plus clinical nodal status cN","url":"https://euclinicaltrials.eu/ctis-public/view/2024-514386-19-00","terms":["radioligand","lutetium","PSMA"],"refs":["prostate-high-risk","prostate","psma"]},{"ctNumber":"2024-519346-75-00","title":"Radiometabolic Therapy (RMT) with 177Lu PSMA in PSMA PET/CT positive advanced/metastatic tumours: a basket trial (LUBASKET)","sponsor":"Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.","phase":"Therapeutic exploratory (Phase II)","countries":["Italy"],"started":"25/05/2023","conditions":"PSMA PET/CT positive advanced/metastatic tumours","url":"https://euclinicaltrials.eu/ctis-public/view/2024-519346-75-00","terms":["PSMA"],"refs":["psma-pet","lu177-radioligand-therapy","lu-177","psma"]},{"ctNumber":"2022-502373-42-00","title":"Metastasis-directed therapy for oligorecurrent prostate cancer : A randomized phase III trial.","sponsor":"UZ Leuven","phase":"Therapeutic confirmatory (Phase III)","countries":["Belgium","Italy"],"started":"25/04/2022","conditions":"Oligorecurrent hormone-sensitive prostate cancer patients","url":"https://euclinicaltrials.eu/ctis-public/view/2022-502373-42-00","terms":["PSMA"],"refs":["prostate"]},{"ctNumber":"2024-517899-38-00","title":"EORTC-2361-GUCG: Phase II trial evaluating the efficacy of 177Lutetium-PSMA treatment in patients with metastatic clear cell Renal Carcinoma Cell with progressive disease on first-line or second-line systemic treatment (RENALUT)","sponsor":"Europese Organisatie Voor Onderzoek En Behandeling Van Kanker Organisation Europeenne Pour La Recherche Et Le Traitement Du Cancer European Organi","phase":"Therapeutic exploratory (Phase II)","countries":["Spain","France","Belgium"],"started":"25/02/2026","conditions":"Clear Cell Renal Cell Carcinoma (ccRCC)","url":"https://euclinicaltrials.eu/ctis-public/view/2024-517899-38-00","terms":["radiopharmaceutical","PSMA"],"refs":["rcc","psma"]},{"ctNumber":"2024-512831-66-00","title":"A Multicenter, Open-label, Interventional Phase I Trial to Determine the Dose and Evaluate the Pharmacokinetics (PK) and Safety of Lutetium Lu 177 Edotreotide Targeted Radiopharmaceutical Therapy (RPT) as Monotherapy or Following Standard of Care (SoC) for the Treatment of Somatostatin Receptor-positive Tumors in the Pediatric Population (KinLET)","sponsor":"ITM Solucin GmbH","phase":"Human Pharmacology (Phase I)- Other","countries":["Italy","Spain","France"],"started":"24/10/2025","conditions":"Pediatric participants aged two to less than 18 years old with somatostatin receptor positive (SSTR-positive) solid tumors or lymphoma, recurrent/refractory to at least one prior line of therapy","url":"https://euclinicaltrials.eu/ctis-public/view/2024-512831-66-00","terms":["lutetium","radiopharmaceutical"],"refs":["ga-68-dotatoc"]},{"ctNumber":"2024-514785-39-00","title":"\"Imaging with 68Ga-DOTA-peptides and peptide receptor radionuclide therapy with 177Lu-DOTA-peptides of gastroenteropancreatic neuroendocrine tumors: interest of intra-arterial hepatic infusion in patients with dominant liver metastases\" \"LUTARTERIAL\"","sponsor":"Centre Hospitalier Universitaire De Bordeaux","phase":"Therapeutic exploratory (Phase II)","countries":["France"],"started":"24/09/2021","conditions":"Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults","url":"https://euclinicaltrials.eu/ctis-public/view/2024-514785-39-00","terms":["radiopharmaceutical"],"refs":["prrt","neuroendocrine","lu177-radioligand-therapy","lu-177","ga-68","dota-chelation"]},{"ctNumber":"2024-514181-39-00","title":"Intrapatient comparison of 68Ga-gozetotide (PSMA) PET and 89Zr-girentuximab PET in clear cell renal cell carcinoma (ISEE-RCC)","sponsor":"Stichting Radboud universitair medisch centrum","phase":"Therapeutic confirmatory (Phase III)","countries":["Netherlands"],"started":"23/09/2025","conditions":"Metastatic renal cell carcinoma","url":"https://euclinicaltrials.eu/ctis-public/view/2024-514181-39-00","terms":["PSMA"],"refs":["rcc","psma","ga-68","zr-89"]},{"ctNumber":"2024-515178-28-00","title":"Evaluation of Multiparametric dynamic whole-body 68Ga-PSMA PET imaging for Hepatocellular Carcinoma recurrence. HIMIKO study.","sponsor":"Centre Hospitalier Universitaire De Nantes","phase":"Phase I and Phase II (Integrated)- Other","countries":["France"],"started":"23/09/2025","conditions":"Hepatocellular carcinoma","url":"https://euclinicaltrials.eu/ctis-public/view/2024-515178-28-00","terms":["PSMA"],"refs":["hcc","psma-pet","psma","ga-68"]},{"ctNumber":"2024-518171-59-00","title":"Multi-institutional Evaluation of the Cost-effectiveness of PSMA-PET/CT for the Detection of Pelvic Lymph Node Invasion in Newly Diagnosed Prostate Cancer Patients (PSMA-SELECT).","sponsor":"Canisius Wilhelmina Ziekenhuis","phase":"Phase III and phase IV (Integrated)","countries":["Netherlands"],"started":"23/01/2025","conditions":"Prostate Cancer","url":"https://euclinicaltrials.eu/ctis-public/view/2024-518171-59-00","terms":["radiopharmaceutical","PSMA"],"refs":["prostate","psma"]},{"ctNumber":"2022-501019-15-00","title":"Phase I/II study assessing radioligand therapy (RLT) using 177Lu-PentixaTher for relapsed/refractory CXCR4+ acute leukemia.","sponsor":"Centre Hospitalier Universitaire De Nantes","phase":"Phase I and Phase II (Integrated)- Other","countries":["France"],"started":"22/10/2024","conditions":"Acute Leukemia","url":"https://euclinicaltrials.eu/ctis-public/view/2022-501019-15-00","terms":["radioligand"],"refs":["radioligand-therapy","lu177-radioligand-therapy","cxcr4","lu-177"]},{"ctNumber":"2024-518985-29-02","title":"DUET-study: A FEASIBILITY STUDY OF 177LU-PSMA RADIOLIGAND THERAPY ALTERNATED WITH RADIUM-223 IN PATIENTS WITH BONE-METASTATIC, OLIGO-METASTATIC HORMONE-SENSITIVE PROSTATE CANCER AFTER CURATIVE THERAPY.","sponsor":"Amsterdam UMC Stichting","phase":"Phase I and Phase II (Integrated)- First administration to humans","countries":["Netherlands"],"started":"21/11/2024","conditions":"Prostate cancer","url":"https://euclinicaltrials.eu/ctis-public/view/2024-518985-29-02","terms":["radioligand","lutetium","PSMA"],"refs":["prostate-mhspc","radioligand-therapy","prostate","ra-223","lu177-radioligand-therapy","lu-177","psma"]},{"ctNumber":"2024-510707-11-00","title":"Prostate-only, dose-escalated radiotherapy plus concomitant androgen deprivation therapy in primary localized, NCCN high risk and MMAI classifier low or intermediate-risk prostate cancer – a prospective, single-arm, phase II study","sponsor":"Linac-Pet Scan Opco Limited","phase":"Therapeutic exploratory (Phase II)","countries":["Cyprus"],"started":"21/10/2024","conditions":"Prostate cancer","url":"https://euclinicaltrials.eu/ctis-public/view/2024-510707-11-00","terms":["PSMA"],"refs":["prostate"]},{"ctNumber":"2024-512906-24-00","title":"Biodistribution Evaluation to Reduce Administered Radiopharmaceutical Dose on LOng Axial Field of VieW PET Scanners – BELOW trial","sponsor":"Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting","phase":"Human Pharmacology (Phase I)- Other","countries":["Netherlands"],"started":"21/03/2025","conditions":"Cancer","url":"https://euclinicaltrials.eu/ctis-public/view/2024-512906-24-00","terms":["radiopharmaceutical"],"refs":[]},{"ctNumber":"2024-513097-21-00","title":"Phase 1 study to evaluate [18F]ACI-19626 as a potential PET radioligand for imaging TDP-43 inclusions in the brain of patients with suspected TDP-43 proteinopathies compared with healthy controls","sponsor":"AC Immune SA","phase":"Human Pharmacology (Phase I)- First administration to humans","countries":["Netherlands"],"started":"20/11/2024","conditions":"Alzheimer's Disease, Familial and sporadic Amyotrophic lateral sclerosis, Familial and sporadic Frontotemporal dementia, Suspected limbic predominant age-related TDP-43 Encephalopathy (LATE)","url":"https://euclinicaltrials.eu/ctis-public/view/2024-513097-21-00","terms":["radioligand"],"refs":["alzheimers-disease"]},{"ctNumber":"2024-517971-19-01","title":"Prospective, monocentric, exploratory phase II study for the evaluation of the diagnostic use of the tracer PET (18F) -Flutemetamol (Vizamyl®) in patients with cardiac amyloidosis","sponsor":"Fondazione Toscana Gabriele Monasterio","phase":"Therapeutic exploratory (Phase II)","countries":["Italy"],"started":"20/09/2023","conditions":"cardiac amyloidosis","url":"https://euclinicaltrials.eu/ctis-public/view/2024-517971-19-01","terms":["radiopharmaceutical"],"refs":["cardiac-amyloidosis-attr","f-18-flutemetamol"]},{"ctNumber":"2023-507486-26-00","title":"First-in-human study of 225Ac-PSMA-Trillium (BAY 3563254) in participants with advanced metastatic castration-resistant prostate cancer (mCRPC)","sponsor":"Bayer Consumer Care AG","phase":"Human Pharmacology (Phase I)- First administration to humans","countries":["Belgium","Finland","Italy","Sweden","Netherlands"],"started":"20/08/2024","conditions":"Advanced metastatic castration-resistant prostate cancer with prostate specific membrane antigen (PSMA) expression","url":"https://euclinicaltrials.eu/ctis-public/view/2023-507486-26-00","terms":["PSMA"],"refs":["prostate-mcrpc","prostate","ac225-psma","ac-225","psma"]},{"ctNumber":"2023-504254-35-00","title":"A multicenter, open-label, non-randomized Phase 1/2 study to assess safety, tolerability, and imaging characteristics of [68Ga]Ga-DPI-4452 and to assess safety, tolerability, and efficacy of [177Lu]Lu-DPI-4452 in patients with unresectable locally advanced or metastatic solid tumors","sponsor":"ITM Oncologics GmbH","phase":"Phase I and Phase II (Integrated)- First administration to humans","countries":["France","Belgium"],"started":"20/06/2023","conditions":"Unresectable locally advanced or metastatic solid tumors: • Clear cell renal cell carcinoma (ccRCC) • Pancreatic ductal adenocarcinoma (PDAC) • Colorectal Cancer (CRC) (Part A) • Urothelial carcinoma ","url":"https://euclinicaltrials.eu/ctis-public/view/2023-504254-35-00","terms":["radioligand","radiopharmaceutical"],"refs":["pancreatic-cancer","rcc","urothelial-cancer","colorectal-cancer","nsclc","lu177-radioligand-therapy","lu-177","breast-triple-negative","ga-68"]},{"ctNumber":"2023-503684-42-00","title":"A phase II trial of 177Lutetium-DOTATATE in children with primary refractory or relapsed high-risk neuroblastoma LuDO-N","sponsor":"Karolinska University Hospital","phase":"Therapeutic exploratory (Phase II)","countries":["Denmark","Norway","Lithuania","Netherlands","Sweden","Spain"],"started":"20/02/2026","conditions":"Neuroblastoma","url":"https://euclinicaltrials.eu/ctis-public/view/2023-503684-42-00","terms":["lutetium","radiopharmaceutical"],"refs":["neuroblastoma-high-risk","neuroblastoma"]},{"ctNumber":"2022-501493-19-00","title":"A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of [177Lu]LU-PSMA-I&T versus Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer","sponsor":"Curium Pet France","phase":"Therapeutic confirmatory (Phase III)","countries":["Italy","France","Spain"],"started":"20/02/2023","conditions":"metastatic Castration-Resistant Prostate Cancer (mCRPC)","url":"https://euclinicaltrials.eu/ctis-public/view/2022-501493-19-00","terms":["radioligand","PSMA"],"refs":["prostate-mcrpc","prostate","lu177-radioligand-therapy","lu-177","psma"]},{"ctNumber":"2024-515608-38-00","title":"A Phase I study to evaluate the safety and dosimetry of 68Ga-OncoACP3 in patients with prostate cancer","sponsor":"Philogen S.p.A.","phase":"Human Pharmacology (Phase I)- First administration to humans","countries":["Italy"],"started":"19/03/2025","conditions":"Patients with prostate cancer with: -suspected metastasis who are candidates for initial definitive therapy -suspected recurrence based on elevated serum prostate-specific antigen (PSA) level (i.e., a","url":"https://euclinicaltrials.eu/ctis-public/view/2024-515608-38-00","terms":["PSMA"],"refs":["prostate","lu177-radioligand-therapy","lu-177","psma","ga-68"]},{"ctNumber":"2022-502254-13-00","title":"Metastasis-directed therapy in oligoprogressive castration-refractory prostate cancer: a randomized phase 3 trial","sponsor":"UZ Leuven","phase":"Therapeutic confirmatory (Phase III)","countries":["Belgium","Denmark"],"started":"18/12/2023","conditions":"Oligoprogressive metastatic castration-refractory prostate cancer","url":"https://euclinicaltrials.eu/ctis-public/view/2022-502254-13-00","terms":["PSMA"],"refs":["prostate"]},{"ctNumber":"2022-501343-33-00","title":"(21492 ARASTEP) A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer","sponsor":"Bayer Consumer Care AG, Bayer AG","phase":"Therapeutic confirmatory (Phase III)","countries":["Spain","Denmark","Italy","Sweden","Finland","Germany","Austria","France","Belgium","Czechia","Hungary","Portugal","Netherlands","Poland"],"started":"18/10/2023","conditions":"Biochemically recurrent prostate cancer","url":"https://euclinicaltrials.eu/ctis-public/view/2022-501343-33-00","terms":["PSMA"],"refs":["prostate-bcr","prostate"]},{"ctNumber":"2022-502623-22-00","title":"A study to learn how safe the study treatment actinium-225-macropa-pelgifatamab (BAY3546828) is, how it affects the body, how it moves into, through and out of the body, and about its anticancer activity in men with advanced metastatic castration-resistant prostate cancer (mCRPC)","sponsor":"Bayer AG","phase":"Human Pharmacology (Phase I)- First administration to humans","countries":["Finland","Netherlands","Italy","Sweden"],"started":"18/09/2023","conditions":"Metastatic castration-resistant prostate cancer","url":"https://euclinicaltrials.eu/ctis-public/view/2022-502623-22-00","terms":["actinium"],"refs":["prostate-mcrpc","prostate","ac-225"]},{"ctNumber":"2024-514168-15-00","title":"Tolerability of concurrent EBRT + Lu-PSMA for node-positive prostate cancer (PROQURE-1)","sponsor":"Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting","phase":"Human Pharmacology (Phase I)- Other","countries":["Netherlands"],"started":"17/12/2021","conditions":"N+M0 prostate cancer","url":"https://euclinicaltrials.eu/ctis-public/view/2024-514168-15-00","terms":["PSMA"],"refs":["prostate","psma"]},{"ctNumber":"2024-513638-39-00","title":"A clinical study to determine the dose and assess safety and efficacy of radioimmuntherapy in patients with glioblastoma, where Lutetium 177 labelled 6A10 antibody Fab fragments are applied to the tumor resection cavity.","sponsor":"Universitaetsklinikum Muenster AöR","phase":"Human Pharmacology (Phase I)- First administration to humans","countries":["Germany"],"started":"17/10/2022","conditions":"Surgically treated high grade glioma after concomitant radiochemotherapy and adjuvant standard chemotherapy, with no or small stable tumor residue","url":"https://euclinicaltrials.eu/ctis-public/view/2024-513638-39-00","terms":["lutetium"],"refs":["glioblastoma"]},{"ctNumber":"2023-505884-35-00","title":"Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with long-acting Somatostatin Analogues – ATSA trial","sponsor":"Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting","phase":"Therapeutic use (Phase IV)","countries":["Netherlands"],"started":"17/06/2024","conditions":"The study population includes all patients aged over 18 with a neuroendocrine tumor grade I and II and a clinical indication for PRRT.","url":"https://euclinicaltrials.eu/ctis-public/view/2023-505884-35-00","terms":["lutetium"],"refs":["prrt"]},{"ctNumber":"2023-509787-15-00","title":"PEACE 7 : A randomized Phase III trial with a factorial design evaluating the efficacy and safety of darolutamide and stereotactic dose escalated radiotherapy in patients with localized prostate cancer and high-risk features ofrelapse, from the Prostate Cancer Consortium in Europe (PEACE).","sponsor":"Unicancer","phase":"Therapeutic confirmatory (Phase III)","countries":["France","Spain"],"started":"17/02/2025","conditions":"Patients with localised prostate cancer and high-risk features of relapse (minimum 2 high-risk criteria from National Comprehensive Cancer Network (NCCN) classification)1 and with no detectable metast","url":"https://euclinicaltrials.eu/ctis-public/view/2023-509787-15-00","terms":["PSMA"],"refs":["prostate","psma-pet","psma"]},{"ctNumber":"2022-502440-12-00","title":"Study evaluating PSMA targeted radionuclide therapy in adult patients with metastatic clear cell renal cancer","sponsor":"Centre Leon Berard, Centre Leon Berard","phase":"Phase I and Phase II (Integrated)- Other","countries":["France"],"started":"16/11/2023","conditions":"metastatic clear cell renal cancer with progressive disease after 2 lines of therapy in the advanced/metastatic setting including at least 1 line of anti-VEGFR and 1 line of immunotherapy.","url":"https://euclinicaltrials.eu/ctis-public/view/2022-502440-12-00","terms":["PSMA"],"refs":["psma"]},{"ctNumber":"2024-520155-24-00","title":"A Phase II, randomized, open-label, multi-center study of JSB462 in combination with lutetium (177Lu) vipivotide tetraxetan in adult male patients with PSMA-positive metastatic castration resistant prostate cancer (mCRPC)","sponsor":"Novartis Pharma AG","phase":"Therapeutic exploratory (Phase II)","countries":["Netherlands","Austria","Germany","Italy","France","Czechia","Spain"],"started":"16/10/2025","conditions":"Metastatic castration resistant prostate cancer (mCRPC)","url":"https://euclinicaltrials.eu/ctis-public/view/2024-520155-24-00","terms":["lutetium","PSMA"],"refs":["prostate","prostate-mcrpc","lu177-radioligand-therapy","lu-177","psma"]},{"ctNumber":"2023-507772-50-00","title":"PSMAfore: A phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of androgen receptor-directed therapy in the Treatment of Taxane Naïve Men with Progressive Metastatic Castrate Resistant Prostate Cancer","sponsor":"Novartis Pharma AG","phase":"Therapeutic confirmatory (Phase III)","countries":["Spain","Slovakia","Czechia","Sweden","Belgium","France","Austria","Germany","Netherlands"],"started":"16/06/2021","conditions":"PSMA-positive metastatic castration-resistant prostate cancer","url":"https://euclinicaltrials.eu/ctis-public/view/2023-507772-50-00","terms":["radiopharmaceutical","PSMA"],"refs":["prostate-mcrpc","prostate","pluvicto","lu177-radioligand-therapy","lu-177","psma"]},{"ctNumber":"2023-505024-62-01","title":"Fractionated stereotactic radiotherapy plus second-generation antiandrogen for oligometastatic patients with castration-resistant prostate cancer. Phase II Spanish study, prospective, multicenter. (OLIGORESIST)","sponsor":"Instituto de investigación en Oncología radioterápica FEOR (Fundación Española de Oncología RT)","phase":"Therapeutic exploratory (Phase II)","countries":["Spain"],"started":"16/05/2024","conditions":"Oligometastatic patients with castration-resistant prostate cancer","url":"https://euclinicaltrials.eu/ctis-public/view/2023-505024-62-01","terms":["PSMA"],"refs":["prostate"]},{"ctNumber":"2025-521581-10-00","title":"A Phase 1/2 First-Time-in-Human, open-label, multicenter, dose escalation and expansion study of GSK5458514 PSMA targeting T cell engager alone or in combination with other anti-cancer agents in adult participants with metastatic castration-resistant prostate cancer (mCRPC)","sponsor":"Glaxosmithkline Research & Development Limited","phase":"Phase I and Phase II (Integrated)- First administration to humans","countries":["France","Spain"],"started":"16/01/2026","conditions":"Neoplasms, Prostate","url":"https://euclinicaltrials.eu/ctis-public/view/2025-521581-10-00","terms":["PSMA"],"refs":["prostate-mcrpc","prostate","psma"]},{"ctNumber":"2024-517098-26-00","title":"Multicentric trial evaluating the correlation between early PSMA-PET change and response to systemic treatment for first-line metastatic clear cell Renal Carcinoma Cell.","sponsor":"Cliniques Universitaires Saint-Luc","phase":"Therapeutic exploratory (Phase II)","countries":["Belgium"],"started":"15/07/2026","conditions":"metastatic clear cell Renal Carcinoma Cell","url":"https://euclinicaltrials.eu/ctis-public/view/2024-517098-26-00","terms":["PSMA"],"refs":["psma"]},{"ctNumber":"2024-519516-14-01","title":"The effect of androgen deprivation therapy on the expression of prostate specific membrane antigen (PSMA) in treatment naive metastatic prostate cancer","sponsor":"Turku University Hospital","phase":"Therapeutic exploratory (Phase II)","countries":["Finland"],"started":"15/04/2019","conditions":"Metastatic prostate cancer, Prostate cancer","url":"https://euclinicaltrials.eu/ctis-public/view/2024-519516-14-01","terms":["PSMA"],"refs":["prostate","psma"]},{"ctNumber":"2022-501892-14-00","title":"Evaluation of PSMA-PET and mpMRI in high-risk prostate cancer – using histopathologic validation","sponsor":"Region Vasterbotten, Umea University","phase":"Therapeutic confirmatory (Phase III)","countries":["Sweden"],"started":"14/10/2024","conditions":"Prostate cancer","url":"https://euclinicaltrials.eu/ctis-public/view/2022-501892-14-00","terms":["PSMA"],"refs":["prostate-high-risk","prostate","psma"]},{"ctNumber":"2024-514196-17-00","title":"A no-profit, open-label, phase II pilot study on the efficacy and safety of Alpelisib in patients with Dent 2 disease (ALPEDENT study)","sponsor":"Ospedale Pediatrico Bambino Gesu","phase":"Therapeutic exploratory (Phase II)","countries":["Italy"],"started":"14/03/2025","conditions":"Dent 2 disease","url":"https://euclinicaltrials.eu/ctis-public/view/2024-514196-17-00","terms":["radiopharmaceutical"],"refs":[]},{"ctNumber":"2024-519377-18-00","title":"Neoadjuvant [177Lu]Lu-PSMAI&T radioligand therapy (PSMA-RLT) for patients with oligometastatic prostate cancer diagnosed using [68Ga]Ga-PSMA-11 PET imaging followed by radical prostatectomy: A Prospective Phase II Pilot Study","sponsor":"Medical University Of Vienna","phase":"Therapeutic exploratory (Phase II)","countries":["Austria"],"started":"14/01/2025","conditions":"Prostate Carcinoma","url":"https://euclinicaltrials.eu/ctis-public/view/2024-519377-18-00","terms":["radioligand","radiopharmaceutical","PSMA"],"refs":["radioligand-therapy","prostate","lu177-radioligand-therapy","lu-177","psma","ga-68"]},{"ctNumber":"2022-501551-90-00","title":"Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (THUNDER): A Two-part Phase 2/3 Trial","sponsor":"Ziekenhuis Aan De Stroom","phase":"Phase II and Phase III (Integrated)","countries":["Belgium","Spain"],"started":"13/12/2023","conditions":"Prostate cancer","url":"https://euclinicaltrials.eu/ctis-public/view/2022-501551-90-00","terms":["PSMA"],"refs":["prostate-high-risk","prostate"]},{"ctNumber":"2025-521227-70-00","title":"A First-In-Human, phase I/IIa, open-label trial assessing safety, tolerability, and feasibility of repeated administrations of a novel autologous tumor-infiltrating lymphocyte-based immunotherapy in patients with metastatic colorectal or prostate cancer","sponsor":"CuraCell Holding AB","phase":"Phase I and Phase II (Integrated)- First administration to humans","countries":["Germany"],"started":"13/11/2025","conditions":"Patients with locally advanced or metastatic prostate cancer (PCa) or metastatic colorectal cancer. Participants should have progressive disease.","url":"https://euclinicaltrials.eu/ctis-public/view/2025-521227-70-00","terms":["PSMA"],"refs":["colorectal-cancer","prostate"]},{"ctNumber":"2024-517901-97-00","title":"AD ASTRA (Androgen Deprivation with Apalutamide and STereotactic RAdiotherapy)","sponsor":"Vychodoslovensky Onkologicky Ustav a.s.","phase":"Therapeutic exploratory (Phase II)","countries":["Slovakia"],"started":"13/06/2023","conditions":"Localized or a locally advanced high-risk prostate cancer","url":"https://euclinicaltrials.eu/ctis-public/view/2024-517901-97-00","terms":["PSMA"],"refs":["prostate-high-risk","prostate"]},{"ctNumber":"2024-516556-17-00","title":"Multicentre Evaluation of Clinical Applications of Innovative PET/MRI with a 68Ga-PSMA-11 Radiotracer when Planning a Personalised Therapy in Prostate Cancer Patients","sponsor":"Medical University Of Bialystok","phase":"Therapeutic confirmatory (Phase III)","countries":["Poland"],"started":"12/12/2022","conditions":"Intermediate and high-risk prostate cancer","url":"https://euclinicaltrials.eu/ctis-public/view/2024-516556-17-00","terms":["PSMA"],"refs":["prostate-high-risk","prostate","psma","ga-68"]},{"ctNumber":"2023-505852-23-00","title":"A Randomized, Controlled, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer, Assessed by PSMA-PET, with an Observational Cohort","sponsor":"Janssen - Cilag International","phase":"Therapeutic confirmatory (Phase III)","countries":["Italy","Portugal","Finland","Sweden","Spain","Denmark","Poland","Slovakia","Belgium","Austria","Hungary","Czechia","Germany"],"started":"12/11/2020","conditions":"High risk recurrent prostate cancer previously treated with radical prostatectomy","url":"https://euclinicaltrials.eu/ctis-public/view/2023-505852-23-00","terms":["PSMA"],"refs":["prostate","psma"]},{"ctNumber":"2024-515049-41-00","title":"Surgical treatment with or without apalutamide in subjects with high risk prostate cancer who are candidates for radical prostatectomy and staged as oligometastatic with PSMA-PET (STAPLE)","sponsor":"Universita' Degli Studi Di Torino","phase":"Therapeutic exploratory (Phase II)","countries":["Italy"],"started":"12/07/2024","conditions":"metastatic prostate cancer","url":"https://euclinicaltrials.eu/ctis-public/view/2024-515049-41-00","terms":["PSMA"],"refs":["prostate","psma"]},{"ctNumber":"2023-506965-72-00","title":"An open-label, single-center study to evaluate the safety and test-retest characteristics of [11C]MODAG-005 as PET radioligand for imaging pathological alpha-synuclein deposition in the brains of patients with Parkinson’s disease (PD) or Multiple System Atrophy (MSA) compared to age-matched healthy controls (AMHC)","sponsor":"Modag GmbH","phase":"Human Pharmacology (Phase I)- First administration to humans","countries":["Germany"],"started":"12/06/2026","conditions":"Parkinson Disease, Multiple System Atrophy, Healthy Volunteer","url":"https://euclinicaltrials.eu/ctis-public/view/2023-506965-72-00","terms":["radioligand"],"refs":["alpha-synuclein"]},{"ctNumber":"2025-524594-16-00","title":"A Phase I study to evaluate the safety and dosimetry of imaging with 68Ga-OncoACP3 in prostate cancer.","sponsor":"Philogen S.p.A.","phase":"Human Pharmacology (Phase I)- First administration to humans","countries":["Italy"],"started":"12/05/2026","conditions":"Patients with prostate cancer with: - suspected metastasis who are candidates for initial definitive therapy - suspected recurrence based on elevated serum prostate-specific antigen (PSA) level (i.e.,","url":"https://euclinicaltrials.eu/ctis-public/view/2025-524594-16-00","terms":["PSMA"],"refs":["prostate","lu177-radioligand-therapy","lu-177","psma","ga-68"]},{"ctNumber":"2024-518236-36-00","title":"Efficacy and safety of adjuvant peptide receptor radionuclide therapy after curative surgery of locoregional limited small intestine neuroendocrine neoplasia – a multi-center, prospective, open-label, two-arm parallel group, randomized, controlled, phase III study","sponsor":"Philipps-Universitaet Marburg","phase":"Therapeutic confirmatory (Phase III)","countries":["Germany"],"started":"12/03/2026","conditions":"Locoregionally restricted (stage III) small intestinal neuroendocrine neoplasms (SI-NEN)","url":"https://euclinicaltrials.eu/ctis-public/view/2024-518236-36-00","terms":["radioligand"],"refs":["prrt"]},{"ctNumber":"2024-512338-13-00","title":"A Phase I, open-label, multi-center study of radiation dosimetry, safety, and tolerability of extended lutetium (177Lu) vipivotide tetraxetan treatment in chemo-naïve adults with metastatic castration-resistant prostate cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) study","sponsor":"Novartis Pharma AG","phase":"Human Pharmacology (Phase I)- Other","countries":["Spain","Germany","Netherlands"],"started":"11/11/2024","conditions":"Metastatic Castration-Resistant Prostate Cancer","url":"https://euclinicaltrials.eu/ctis-public/view/2024-512338-13-00","terms":["lutetium","radiopharmaceutical","PSMA"],"refs":["prostate-mcrpc","prostate","lu177-radioligand-therapy","lu-177"]},{"ctNumber":"2023-506153-38-00","title":"A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy","sponsor":"Janssen - Cilag International","phase":"Therapeutic confirmatory (Phase III)","countries":["Spain","Netherlands","France","Germany","Italy","Czechia","Poland"],"started":"11/07/2019","conditions":"High-risk localized or locally advanced prostate cancer","url":"https://euclinicaltrials.eu/ctis-public/view/2023-506153-38-00","terms":["PSMA"],"refs":["prostate-high-risk","prostate"]},{"ctNumber":"2024-512043-22-00","title":"ReaLuP : an open label, single arm phase IIb study of re-treatment with [177Lu]Lu-PSMA in men with metastatic castration resistance prostate cancer","sponsor":"Hospices Civils De Lyon","phase":"Therapeutic exploratory (Phase II)","countries":["France"],"started":"11/04/2025","conditions":"Metastatic prostate cancer","url":"https://euclinicaltrials.eu/ctis-public/view/2024-512043-22-00","terms":["radiopharmaceutical","PSMA"],"refs":["prostate","lu177-radioligand-therapy","lu-177","psma"]},{"ctNumber":"2024-513586-39-00","title":"A Randomised, Double-blind, Placebo-controlled, Phase III Study of Adjuvant Saruparib (AZD5305) in Patients with BRCAm Localised High-risk Prostate Cancer Receiving Radiotherapy with Androgen Deprivation Therapy (EvoPAR-Prostate02)","sponsor":"AstraZeneca AB","phase":"Therapeutic confirmatory (Phase III)","countries":["Austria","Sweden","Spain","France","Netherlands","Germany","Belgium","Finland","Hungary","Poland","Italy"],"started":"10/12/2025","conditions":"Prostate Cancer","url":"https://euclinicaltrials.eu/ctis-public/view/2024-513586-39-00","terms":["PSMA"],"refs":["prostate-high-risk","prostate"]},{"ctNumber":"2022-500838-28-00","title":"A Phase I/II Study of Neoadjuvant, Intra-arterial Administration of [177Lu]Lu-PSMA-617 in Subjects with High-risk, Localised or Locally Advanced Prostate Cancer who are Candidates for Radical Prostatectomy (LUPUS)","sponsor":"Universitaetsklinikum Essen AöR","phase":"Phase I and Phase II (Integrated)- Other","countries":["Germany"],"started":"10/09/2024","conditions":"high-risk localized or locally advanced prostate cancer","url":"https://euclinicaltrials.eu/ctis-public/view/2022-500838-28-00","terms":["PSMA"],"refs":["prostate-high-risk","prostate","lu177-radioligand-therapy","lu-177","psma"]},{"ctNumber":"2024-519348-34-00","title":"[177Lu]Lu-PSMAI&T radioligand therapy (PSMA-RLT) for patients with prostate cancer and biochemical but not radio-morphological local recurrence after primary therapy with curative intent: A Prospective Phase II Pilot Study","sponsor":"Medical University Of Vienna","phase":"Therapeutic exploratory (Phase II)","countries":["Austria"],"started":"09/12/2024","conditions":"prostate carcinoma","url":"https://euclinicaltrials.eu/ctis-public/view/2024-519348-34-00","terms":["radioligand","radiopharmaceutical","PSMA"],"refs":["radioligand-therapy","prostate","lu177-radioligand-therapy","lu-177","psma"]},{"ctNumber":"2023-506609-21-00","title":"Sleep and Temperature Disturbance as risk factors for Alzheimer's Disease in Down Syndrome: a Longitudinal Study.","sponsor":"Fundacio Institut De Recerca De L Hospital De La Santa Creu I Sant Pau","phase":"Therapeutic exploratory (Phase II)","countries":["Spain"],"started":"09/04/2024","conditions":"Alzheimer´s Disease., Down Syndrome.","url":"https://euclinicaltrials.eu/ctis-public/view/2023-506609-21-00","terms":["radiopharmaceutical"],"refs":["alzheimers-disease"]},{"ctNumber":"2022-503040-41-00","title":"An international prospective open-label, multi-center, randomized, non-comparative phase II study of lutetium [177Lu] vipivotide tetraxetan (AAA617) alone and lutetium [177Lu] vipivotide tetraxetan (AAA617) in combination with androgen receptor pathway inhibitors in patients with PSMA PET scan positive castration-resistant prostate cancer (PSMACare)","sponsor":"Novartis Pharma AG","phase":"Therapeutic exploratory (Phase II)","countries":["Spain","Germany","Italy","Netherlands","Czechia","France","Poland"],"started":"09/02/2024","conditions":"PSMA PET scan positive Castration-Resistant Prostate Cancer (CRPC)","url":"https://euclinicaltrials.eu/ctis-public/view/2022-503040-41-00","terms":["radioligand","lutetium","radiopharmaceutical","PSMA"],"refs":["prostate","psma-pet","lu177-radioligand-therapy","lu-177","psma"]},{"ctNumber":"2024-511537-35-00","title":"An open-label, multicentre, integrated Phase 1 & 2 study to evaluate the safety, tolerability, radiation dosimetry and anti-tumour activity of Lutetium (177Lu) rhPSMA-10.1 injection in men with metastatic castrate-resistant prostate cancer","sponsor":"Blue Earth Therapeutics Limited","phase":"Phase I and Phase II (Integrated)- Other","countries":["Germany","Belgium","Netherlands"],"started":"09/02/2024","conditions":"Metastatic castration-resistant prostate cancer (mCRPC)","url":"https://euclinicaltrials.eu/ctis-public/view/2024-511537-35-00","terms":["lutetium","radiopharmaceutical","PSMA"],"refs":["prostate-mcrpc","prostate","radiohybrid-chemistry","lu177-radioligand-therapy","lu-177"]},{"ctNumber":"2023-504912-13-00","title":"177Lu-PSMA as a systemic adjuvant treatment in patients with high and very high risk prostate cancer after radical treatment with locoregional teleradiotherapy and hormone therapy.","sponsor":"Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie-Panstwowy Instytut Badawczy","phase":"Therapeutic exploratory (Phase II)","countries":["Poland"],"started":"09/01/2025","conditions":"Prostate Cancer","url":"https://euclinicaltrials.eu/ctis-public/view/2023-504912-13-00","terms":["PSMA"],"refs":["prostate-high-risk","prostate","lu177-radioligand-therapy","lu-177","psma"]},{"ctNumber":"2024-513303-14-00","title":"Single microdose trial - CXCR4 PET tracer - Pharmacokinetics and pharmacodynamics of [68Ga]Ga-R54, a CXCR4-targeted radiopharmaceutical in patients with advanced solid tumors.","sponsor":"IRCCS Istituto Nazionale Tumori Fondazione Pascale","phase":"Human Pharmacology (Phase I)- First administration to humans","countries":["Italy"],"started":"08/01/2025","conditions":"Advanced solid neoplasm (breast, lung, colon, ovary, pancreas) characterized by positive CXCR4 expression by immunohistochemistry","url":"https://euclinicaltrials.eu/ctis-public/view/2024-513303-14-00","terms":["radiopharmaceutical"],"refs":["cxcr4","ga-68"]},{"ctNumber":"2023-507672-52-00","title":"SatisfACtion: A Phase I/II, open-label, multi-center study of [225Ac]Ac-PSMA-R2 in men with metastatic hormone sensitive prostate cancer (mHSPC) and in men with heavily pre-treated PSMA positive metastatic castration resistant prostate cancer (mCRPC) with or without prior 177Lu-labelled PSMA-targeted radioligand therapy","sponsor":"Novartis Pharma AG","phase":"Phase I and Phase II (Integrated)- First administration to humans","countries":["France"],"started":"07/11/2023","conditions":"PSMA-positive metastatic hormone sensitive prostate cancer (mHSPC) and metastatic Castration-resistant Prostate Cancer (mCRPC) with or without prior 177Lu-PSMA radioligand therapy.","url":"https://euclinicaltrials.eu/ctis-public/view/2023-507672-52-00","terms":["radioligand","radiopharmaceutical","PSMA"],"refs":["prostate-mcrpc","radioligand-therapy","prostate","prostate-mhspc","lu177-radioligand-therapy","lu-177","ac-225","psma"]},{"ctNumber":"2023-504984-17-00","title":"A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination with Anti-cancer Agents in Patients with Advanced Solid Malignancies","sponsor":"AstraZeneca AB","phase":"Phase I and Phase II (Integrated)- First administration to humans","countries":["Sweden","Spain"],"started":"05/10/2022","conditions":"Module 2: IDH-mutant glioma, Module 5: advanced,unresectable or metastatic solid tumours in breast, endometrial, ovarian and prostate cancer, Module 4: advanced,unresectable and HER2+ metastatic solid","url":"https://euclinicaltrials.eu/ctis-public/view/2023-504984-17-00","terms":["radioligand"],"refs":["pancreatic-cancer","prostate","glioblastoma","nsclc","her2"]},{"ctNumber":"2023-504026-19-01","title":"Prospective, Multi-Center Study to Assess the Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients with Newly-Diagnosed High-Risk or Very-High-Risk Prostate Cancer","sponsor":"Abx Advanced Biochemical Compounds - Biomedizinische Forschungsreagenzien GmbH","phase":"Therapeutic confirmatory (Phase III)","countries":["Spain","Netherlands","France","Germany","Italy"],"started":"05/06/2024","conditions":"Prostate Cancer","url":"https://euclinicaltrials.eu/ctis-public/view/2023-504026-19-01","terms":["PSMA"],"refs":["prostate-high-risk","prostate","psma"]},{"ctNumber":"2024-514583-12-00","title":"The Role of Imaging Guided Surgery to Improve the Detection of Lymph Node metastases in Prostate Cancer Patients Treated with Radical Prostatectomy and Extended Pelvic Lymph Node Dissection","sponsor":"Ospedale San Raffaele S.r.l.","phase":"Therapeutic exploratory (Phase II)","countries":["Italy"],"started":"05/05/2021","conditions":"Patients with prostate cancer (PCa) who are candidate to undergo surgical treatment with robot-assisted radical prostatectomy with a risk of lymph nodal invasion > 5% according to preoperative data","url":"https://euclinicaltrials.eu/ctis-public/view/2024-514583-12-00","terms":["PSMA"],"refs":["prostate"]},{"ctNumber":"2024-512859-21-00","title":"Fully hybrid 18F-PSMA PET/MRI as one-stop approach for the diagnosis of clinically significant prostate cancer","sponsor":"Ospedale San Raffaele S.r.l.","phase":"Therapeutic exploratory (Phase II)","countries":["Italy"],"started":"04/12/2023","conditions":"Patients with clinical suspicion of clinically relevant prostate cancer","url":"https://euclinicaltrials.eu/ctis-public/view/2024-512859-21-00","terms":["PSMA"],"refs":["prostate","psma-pet","psma"]},{"ctNumber":"2023-507482-26-00","title":"PEACE 8: Combination of darolutamide and stereotactic body radiation therapy in patients with castration resistant prostate cancer and oligometastases on functional imaging.","sponsor":"Unicancer","phase":"Therapeutic confirmatory (Phase III)","countries":["France","Belgium","Ireland","Spain"],"started":"04/10/2024","conditions":"Castrate-resistant prostate cancer with oligometastases on functional imaging (PSMA or choline/fluciclovine-positron-emission tomography).","url":"https://euclinicaltrials.eu/ctis-public/view/2023-507482-26-00","terms":["PSMA"],"refs":["prostate","psma"]},{"ctNumber":"2023-510532-36-00","title":"In vivo quantification of Hsp90 in the human brain in healthy aging and neurodegeneration using the novel PET radioligand [11C]HSP990","sponsor":"UZ Leuven","phase":"Human Pharmacology (Phase I)- First administration to humans","countries":["Belgium"],"started":"04/09/2024","conditions":"Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Parkinson's Disease","url":"https://euclinicaltrials.eu/ctis-public/view/2023-510532-36-00","terms":["radioligand"],"refs":["alzheimers-disease"]},{"ctNumber":"2022-502408-57-00","title":"PEACE-6 Poor Responders: A randomized phase III trial evaluating the efficacy and safety of 177Lu-PSMA-617 in addition to Standard of Care (SoC) versus SoC alone in de novo metastatic hormone-sensitive prostate cancer (mHSPC) patients having a serum PSA level of ≥ 0.2 ng/mL at 6 to 8 months after systemic treatment initiation for mHSPC.","sponsor":"Unicancer","phase":"Therapeutic confirmatory (Phase III)","countries":["France","Belgium","Ireland","Italy","Spain","Netherlands"],"started":"04/09/2024","conditions":"Novo metastatic hormone-sensitive prostate cancer (mHSPC) patients having a serum PSA level of ≥ 0.2 ng/mL at 6 to 8 months after systemic treatment initiation for mHSPC (i.e. poor responders) in the ","url":"https://euclinicaltrials.eu/ctis-public/view/2022-502408-57-00","terms":["radiopharmaceutical","PSMA"],"refs":["prostate-mhspc","prostate","pluvicto","lu177-radioligand-therapy","lu-177","psma"]},{"ctNumber":"2025-523264-21-00","title":"CIRAANO: Multimodal exploration (including radiopharmaceuticals Amyvid® and Tauvid®) of theater actors, memory athletes, and patients with various memory pathologies: evaluation of mnesic strategies and their cerebral substrates, and contribution to the treatment of memory pathologies.","sponsor":"Institut National De La Sante Et De La Recherche Medicale","phase":"Phase II and Phase III (Integrated)","countries":["France"],"started":"04/06/2026","conditions":"Semantic Variant Primary Progressive Aphasia, Alcohol Use Disorder, Organic amnesia syndrome, Narcolepsy, Alzheimer, Lewy Body Dementia","url":"https://euclinicaltrials.eu/ctis-public/view/2025-523264-21-00","terms":["radiopharmaceutical"],"refs":["f-18-florbetapir","f-18-flortaucipir"]},{"ctNumber":"2023-503208-94-00","title":"A Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of lutetium (177Lu) vipivotide tetraxetan in Adult Participants with Prostate Cancer","sponsor":"Novartis Pharma AG","phase":"Therapeutic use (Phase IV)","countries":["Czechia","Poland","Sweden","Spain","Netherlands","Germany","Belgium","Austria","France","Italy"],"started":"04/04/2024","conditions":"Prostate cancer","url":"https://euclinicaltrials.eu/ctis-public/view/2023-503208-94-00","terms":["lutetium"],"refs":["prostate","lu177-radioligand-therapy","lu-177"]},{"ctNumber":"2023-503925-20-00","title":"An Open-label Dosimetry, Biodistribution, Tolerability and Safety Study of lutetium (177Lu) vipivotide tetraxetan in Patients With Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Moderately and Severely Impaired and with normal Renal Function","sponsor":"Novartis Pharma AG","phase":"Therapeutic exploratory (Phase II)","countries":["Italy","Germany","Spain","France"],"started":"04/04/2024","conditions":"Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) with moderate and severe renal impairment and with normal renal function.","url":"https://euclinicaltrials.eu/ctis-public/view/2023-503925-20-00","terms":["lutetium","radiopharmaceutical","PSMA"],"refs":["prostate-mcrpc","prostate","lu177-radioligand-therapy","lu-177","psma"]},{"ctNumber":"2024-515664-31-00","title":"Phase 1 study to evaluate [18F]ACI-15916 as a potential PET radioligand for imaging α-synuclein deposits in the brain of patients with suspected α-synuclein pathology compared with healthy volunteers","sponsor":"AC Immune S.A.","phase":"Human Pharmacology (Phase I)- First administration to humans","countries":["Sweden"],"started":"04/03/2025","conditions":"Parkinson's Disease, Dementia with Lewy Bodies, Multiple System Atrophy","url":"https://euclinicaltrials.eu/ctis-public/view/2024-515664-31-00","terms":["radioligand"],"refs":[]},{"ctNumber":"2024-514829-36-00","title":"CARLHA-2_AN OPEN LABEL, RANDOMIZED, PHASE III STUDY EVALUATING THE EFFICACY OF ACOMBINATION OF APALUTAMIDE WITH RADIOTHERAPY AND LHRH AGONIST IN HIGH-RISK POST-PROSTATECTOMY BIOCHEMICALLY RELAPSED PROSTATE CANCER PATIENTS","sponsor":"Unicancer","phase":"Therapeutic confirmatory (Phase III)","countries":["France"],"started":"02/12/2019","conditions":"High-risk biochemically-relapsed prostate adenocarcinoma following radical prostatectomy.","url":"https://euclinicaltrials.eu/ctis-public/view/2024-514829-36-00","terms":["PSMA"],"refs":["prostate"]},{"ctNumber":"2023-506717-21-00","title":"Study protocol title: A Phase I/II, open-label, multi-center trial of [177Lu]Lu-NeoB in combination with capecitabine in adult patients with gastrin releasing peptide receptor positive, estrogen receptor-positive, human epidermal growth receptor-2 negative metastatic breast cancer after progression on previous endocrine therapy in combination with a CDK4/6 inhibitor","sponsor":"Novartis Pharma AG","phase":"Phase I and Phase II (Integrated)- Other","countries":["Germany","Spain","France","Netherlands","Portugal","Italy"],"started":"02/10/2024","conditions":"Breast Cancer","url":"https://euclinicaltrials.eu/ctis-public/view/2023-506717-21-00","terms":["lutetium"],"refs":["capecitabine","lu177-radioligand-therapy","lu-177"]},{"ctNumber":"2024-519505-35-00","title":"Evaluating the roLe of Multiplexed PET Imaging in the detection and staging of hepatocellulaR carcinoma and gAstro-entero-pancreatic tumors: a basket diagnostic performance study","sponsor":"Centre Hospitalier Universitaire De Nantes","phase":"Therapeutic confirmatory (Phase III)","countries":["France"],"started":"02/02/2026","conditions":"hepatocellulaR carcinoma, gastro-entero-pancreatic tumors","url":"https://euclinicaltrials.eu/ctis-public/view/2024-519505-35-00","terms":["radiopharmaceutical"],"refs":["hcc"]},{"ctNumber":"2023-506698-36-00","title":"Apa/Enza short study (Shortened 12 months duration of androgen receptor signalling agent in combination with androgen deprivation therapy in patients with low-volume metastatic castration-sensitive prostate cancer: a randomized nationwide trial","sponsor":"Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)","phase":"Therapeutic confirmatory (Phase III)","countries":["Netherlands"],"started":"02/02/2024","conditions":"low-volume metastatic castration-sensitive prostate cancer","url":"https://euclinicaltrials.eu/ctis-public/view/2023-506698-36-00","terms":["PSMA"],"refs":["prostate-mhspc","prostate"]},{"ctNumber":"2022-502956-29-00","title":"An International, Prospective, Open-label, Multi-center, Randomized Phase III Study comparing lutetium (177Lu) vipivotide tetraxetan (AAA617) versus Observation to delay castration or disease recurrence in adult male patients with prostate-specific membrane antigen (PSMA) positive Oligometastatic Prostate Cancer (OMPC)","sponsor":"Novartis Pharma AG","phase":"Therapeutic confirmatory (Phase III)","countries":["France","Czechia","Spain","Belgium","Italy","Slovakia","Germany","Hungary","Austria","Greece","Netherlands"],"started":"01/07/2024","conditions":"Oligometastatic prostate cancer (OMPC)","url":"https://euclinicaltrials.eu/ctis-public/view/2022-502956-29-00","terms":["lutetium","radiopharmaceutical","PSMA"],"refs":["prostate","lu177-radioligand-therapy","lu-177","psma"]},{"ctNumber":"2023-510508-31-01","title":"Longitudinal multicenter head-to-head harmonization of tau PET tracers (HEAD Study)","sponsor":"Fundacio Institut De Recerca De L Hospital De La Santa Creu I Sant Pau","phase":"Therapeutic exploratory (Phase II)","countries":["Spain"],"started":"01/07/2024","conditions":"cognitive impairment","url":"https://euclinicaltrials.eu/ctis-public/view/2023-510508-31-01","terms":["radiopharmaceutical"],"refs":[]},{"ctNumber":"2024-516083-28-00","title":"99mTc-MIP-1404 SPECT/CT for primary PROstate cancer STAging: comparative prospective, randomized trial to present guideline imaging, PROSTAMIP","sponsor":"Turku University Hospital","phase":"Phase II and Phase III (Integrated)","countries":["Finland"],"started":"01/06/2022","conditions":"Prostate cancer","url":"https://euclinicaltrials.eu/ctis-public/view/2024-516083-28-00","terms":["PSMA"],"refs":["prostate","spect","spect-ct","tc-99m","quantitative-spect","ai-in-nuclear-medicine"]},{"ctNumber":"2024-511659-17-00","title":"68Ga-FAPI-46 PET-CT for molecular assessment of fibroblast activation and risk assessment in solid tumors (FAPI Basket)","sponsor":"Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.","phase":"Therapeutic exploratory (Phase II)","countries":["Italy"],"started":"01/05/2023","conditions":"Solid tumors","url":"https://euclinicaltrials.eu/ctis-public/view/2024-511659-17-00","terms":["radioligand"],"refs":["ga-68-fapi-46","ga-68"]},{"ctNumber":"2022-502285-24-00","title":"Open-label clinical phase 1/2 study to assess the safety and efficacy of the SpectraCure P18 System (Interstitial multiple diode lasers and IDOSE® Software) and verteporfin for injection (VFI) for the treatment of recurrent prostate cancer","sponsor":"SpectraCure AB (publ)","phase":"Phase I and Phase II (Integrated)- First administration to humans","countries":["Germany","Sweden"],"started":"01/03/2024","conditions":"Recurrent prostate cancer","url":"https://euclinicaltrials.eu/ctis-public/view/2022-502285-24-00","terms":["PSMA"],"refs":["prostate"]},{"ctNumber":"2022-503036-13-00","title":"Prostate-specific membrane antigen in thyroid and head and neck carcinoma: On the utility of [18F]AlF-PSMA-11 PET in advanced disease","sponsor":"Universitair Ziekenhuis Gent","phase":"Therapeutic exploratory (Phase II)","countries":["Belgium"],"started":"01/02/2024","conditions":"Head and neck squamous cell carcinoma, thyroid carcinoma","url":"https://euclinicaltrials.eu/ctis-public/view/2022-503036-13-00","terms":["PSMA"],"refs":["psma"]},{"ctNumber":"2024-513729-22-01","title":"Phase I study of 225Ac-PSMA I&T in prostate cancer","sponsor":"Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)","phase":"Human Pharmacology (Phase I)- Bioequivalence Study","countries":["Netherlands"],"started":"01/02/2022","conditions":"metastatic prostate cancer","url":"https://euclinicaltrials.eu/ctis-public/view/2024-513729-22-01","terms":["PSMA"],"refs":["prostate","ac-225","psma"]},{"ctNumber":"2024-519995-20-00","title":"MECHANISMS OF NEURONAL RESILIENCE IN ALZHEIMER'S DISEASE AND ITS FOCAL VARIANTS: A MRI/PET STUDY","sponsor":"Institut National De La Sante Et De La Recherche Medicale","phase":"Phase II and Phase III (Integrated)","countries":["France"],"conditions":"Alzheimer's pathology, Maladie d' Alzheimer","url":"https://euclinicaltrials.eu/ctis-public/view/2024-519995-20-00","terms":["radioligand"],"refs":["alzheimers-disease"]},{"ctNumber":"2025-524027-49-00","title":"An open-label, multicentric, phase 1 study to evaluate the safety, tolerability, and radiation dosimetry of endogenous radioligand therapy with (¹⁷⁷Lu)Lutetiumvipivotidtetraxetan in women with metastatic triple negative breast cancer (TNBC)","sponsor":"Universitaetsklinikum Aachen AöR","phase":"Human Pharmacology (Phase I)- Other","countries":["Germany"],"conditions":"Metastatic triple negative breast cancer","url":"https://euclinicaltrials.eu/ctis-public/view/2025-524027-49-00","terms":["radioligand","lutetium","radiopharmaceutical"],"refs":["radioligand-therapy","breast-triple-negative"]},{"ctNumber":"2026-527110-23-00","title":"A phase II, single arm two-phase, clinical study of individually adapted systemic radioligand therapy with 177Lu-PSMA I&T for patients with metastatic, castration-resistant prostate cancer","sponsor":"Region Uppsala","phase":"Therapeutic exploratory (Phase II)","countries":["Sweden"],"conditions":"Prostate cancer","url":"https://euclinicaltrials.eu/ctis-public/view/2026-527110-23-00","terms":["radioligand","PSMA"],"refs":["radioligand-therapy","prostate","lu177-radioligand-therapy","lu-177","psma"]},{"ctNumber":"2024-511898-30-00","title":"Impact of post-Acute respiratory distress syndrome COVID sedation on late neuroinflammation (PET-DEXDOCOVID)","sponsor":"Assistance Publique Hopitaux De Paris","phase":"Therapeutic confirmatory (Phase III)","countries":["France"],"conditions":"Patients who survive a COVID ARDS in intensive care must be weaned off invasive mechanical ventilation as quickly as possible. 60% of these patients present with intensive care delirium, a serious eve","url":"https://euclinicaltrials.eu/ctis-public/view/2024-511898-30-00","terms":["radioligand"],"refs":[]},{"ctNumber":"2025-524942-87-00","title":"Prognostic value of early assessment by ⁶⁸Ga-DOTATATE PET/CT for the treatment of well-differentiated grade 2 gastroenteropancreatic neuroendocrine tumors with ¹⁷⁷Lutetium-oxodotreotide.”","sponsor":"Centre De Lutte Contre Le Cancer Eugene Marquis","phase":"Therapeutic use (Phase IV)","countries":["France"],"conditions":"Gastroenteropancreatic neuroendocrine tumors","url":"https://euclinicaltrials.eu/ctis-public/view/2025-524942-87-00","terms":["lutetium","radiopharmaceutical"],"refs":[]},{"ctNumber":"2026-525776-26-00","title":"Evaluation of the efficacy, safety, and tolerability of lutetium-177-labeled PSMA ligand in patients with progression of adenoid cystic carcinoma originating from the salivary glands - an open, non-commercial clinical trial","sponsor":"Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy","phase":"Therapeutic exploratory (Phase II)","countries":["Poland"],"conditions":"adenoid cystic carcinoma of the salivary glands","url":"https://euclinicaltrials.eu/ctis-public/view/2026-525776-26-00","terms":["lutetium","radiopharmaceutical","PSMA"],"refs":["lu177-radioligand-therapy","lu-177","psma"]},{"ctNumber":"2026-527059-25-00","title":"A Phase Ib/IIa open-label, multicenter, dose-escalation and proof-of-concept trial evaluating Benfo-Oxythiamine (B-OT) as an investigational add-on to standard of care (SOC) lutetium (177Lu) vipivotide tetraxetan therapy (Pluvicto®) in adults with metastatic castration-resistant prostate cancer (mCRPC) and stable disease after two prior cycles of SOC","sponsor":"Benfovir AG","phase":"Phase I and Phase II (Integrated)- Other","countries":["Germany"],"conditions":"metastatic castration-resistant prostate cancer (mCRPC)","url":"https://euclinicaltrials.eu/ctis-public/view/2026-527059-25-00","terms":["lutetium","PSMA"],"refs":["prostate-mcrpc","prostate","pluvicto","lu177-radioligand-therapy","lu-177"]},{"ctNumber":"2023-506032-33-00","title":"PSMA PET For intermediate- or high-risk prostate cancer prior to RadioTherapY: A prospective interventional randomized clinical trial (P4RTY)","sponsor":"Universitaetsklinikum Essen AöR","phase":"Therapeutic confirmatory (Phase III)","countries":["Germany"],"conditions":"Prostate cancer","url":"https://euclinicaltrials.eu/ctis-public/view/2023-506032-33-00","terms":["radiopharmaceutical","PSMA"],"refs":["prostate-high-risk","prostate","psma-pet","psma"]},{"ctNumber":"2024-516319-25-00","title":"Diagnostic Performance of Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computed Tomography (PET/CT) Imaging for Pre-operative Lymph Node Assessment in Intermediate and High-risk Nonmetastasic Prostate Cancer","sponsor":"Centre Hospitalier Regional Et Universitaire De Brest","phase":"Therapeutic exploratory (Phase II)","countries":["France"],"conditions":"Prostate Cancer","url":"https://euclinicaltrials.eu/ctis-public/view/2024-516319-25-00","terms":["radiopharmaceutical","PSMA"],"refs":["prostate","psma"]},{"ctNumber":"2025-524050-34-01","title":"Use of DOTATOC labeled with V-Cu64 in PET-CT imaging of neuroendocrine tumors","sponsor":"Voxel S.A.","phase":"Therapeutic confirmatory (Phase III)","countries":["Poland"],"conditions":"Neoplasms","url":"https://euclinicaltrials.eu/ctis-public/view/2025-524050-34-01","terms":["radiopharmaceutical"],"refs":[]},{"ctNumber":"2024-512754-16-01","title":"A Phase 3, Multicenter, Open-label Study to Test the Diagnostic Performance of Copper Cu 64 PSMA I&T PET/CT in Staging of Men with Newly Diagnosed Unfavorable Intermediate-risk, High-risk or Very High-risk Prostate Cancer Electing to Undergo Radical Prostatectomy with Pelvic Lymph Node Dissection","sponsor":"Curium US LLC","phase":"Therapeutic confirmatory (Phase III)","countries":["France","Spain","Italy"],"conditions":"Prostate cancer","url":"https://euclinicaltrials.eu/ctis-public/view/2024-512754-16-01","terms":["PSMA"],"refs":["prostate-high-risk","prostate","psma"]},{"ctNumber":"2023-505453-40-00","title":"99mTechnetium and Cyanine-5 (HybriD) Prostate Specific Membrane Antigen (PSMA) Tracer-gUided Surgery in ProstAte Cancer - a FeasibiLity Study (DUAL study)","sponsor":"Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting","phase":"Phase I and Phase II (Integrated)- First administration to humans","countries":["Netherlands"],"conditions":"Prostate cancer","url":"https://euclinicaltrials.eu/ctis-public/view/2023-505453-40-00","terms":["PSMA"],"refs":["prostate","psma"]},{"ctNumber":"2026-525526-38-00","title":"PRadR 2 - A single center, open-label, Phase I study evaluating 161Tb-PSMA therapy in adult patients with metastatic clear cell renal cell carcinoma","sponsor":"Centre Leon Berard","phase":"Human Pharmacology (Phase I)- Other","countries":["France"],"conditions":"Metastatic clear cell renal cell carcinoma","url":"https://euclinicaltrials.eu/ctis-public/view/2026-525526-38-00","terms":["PSMA"],"refs":["rcc","tb-161","psma"]},{"ctNumber":"2024-512754-16-00","title":"A Phase 3, Multicenter, Open-label Study to Test the Diagnostic Performance of Copper Cu 64 PSMA I&T PET/CT in Staging of Men with Newly Diagnosed Unfavorable Intermediate-risk, High-risk or Very High-risk Prostate Cancer Electing to Undergo Radical Prostatectomy with Pelvic Lymph Node Dissection","sponsor":"Curium US LLC","phase":"Therapeutic confirmatory (Phase III)","countries":["France","Spain","Italy"],"conditions":"Prostate cancer","url":"https://euclinicaltrials.eu/ctis-public/view/2024-512754-16-00","terms":["PSMA"],"refs":["prostate-high-risk","prostate","psma"]},{"ctNumber":"2026-525181-22-00","title":"ECETEP : Pilot study evaluating PSMA positron emission tomography for monitoring clinically significant prostate cancer after focal HIFU treatment","sponsor":"Centre Hospitalier Universitaire De Toulouse","phase":"Therapeutic use (Phase IV)","countries":["France"],"conditions":"prostate cancer","url":"https://euclinicaltrials.eu/ctis-public/view/2026-525181-22-00","terms":["PSMA"],"refs":["prostate","psma"]},{"ctNumber":"2026-526915-12-00","title":"PET-Guided Navigation with Electromagnetic Tracking during PSMA-RadioGuided Surgery: Innovative Bimodal Detection of Nodal Metastases in Prostate Cancer Patients","sponsor":"Ospedale San Raffaele S.r.l.","phase":"Therapeutic exploratory (Phase II)","countries":["Italy"],"conditions":"Prostate Cancer","url":"https://euclinicaltrials.eu/ctis-public/view/2026-526915-12-00","terms":["PSMA"],"refs":["prostate","psma"]},{"ctNumber":"2025-525110-29-01","title":"Prognostic value assessment of PSMA-T4 examination in the group of patients with triple-negative breast cancer (TNBC) qualified to radical therapy","sponsor":"Narodowe Centrum Badan Jadrowych","phase":"Phase II and Phase III (Integrated)","countries":["Poland"],"conditions":"triple-negative breast cancer","url":"https://euclinicaltrials.eu/ctis-public/view/2025-525110-29-01","terms":["PSMA"],"refs":["breast-triple-negative","psma"]},{"ctNumber":"2025-520482-52-03","title":"Clinical Application of the Androgen Receptor Inhibitor Darolutamide to Upregulate the Prostate-Specific Membrane Antigen (PSMA) Protein Expression in Patients with Hormone Sensitive Prostate Cancer. - The DARO-flare Trial -","sponsor":"Amsterdam UMC Stichting","phase":"Phase I and Phase II (Integrated)- Other","countries":["Netherlands"],"conditions":"Prostate cancer","url":"https://euclinicaltrials.eu/ctis-public/view/2025-520482-52-03","terms":["PSMA"],"refs":["prostate","psma"]},{"ctNumber":"2024-518495-31-00","title":"68Ga/177Lu-PSMA theranostics in recurrent grade 3 and grade 4 glioma","sponsor":"Norwegian University Of Science And Technolology","phase":"Therapeutic exploratory (Phase II)","countries":["Norway"],"conditions":"Recurrent grade 3 and grade 4 glioma","url":"https://euclinicaltrials.eu/ctis-public/view/2024-518495-31-00","terms":["PSMA"],"refs":["glioblastoma","lu177-radioligand-therapy","lu-177","psma","ga-68"]},{"ctNumber":"2024-519358-35-00","title":"An open-label phase 2/3 study to analyse the feasibility and evaluate the safety of intravenous administration of 99mTc-PSMA-T4 in patients with prostate cancer","sponsor":"Narodowe Centrum Badan Jadrowych","phase":"Phase II and Phase III (Integrated)","countries":["Poland"],"conditions":"Feasibility analysis and safety evaluation of [99mTc]Tc-PSMA-T4 in prostate cancer diagnosis and treatment planning.","url":"https://euclinicaltrials.eu/ctis-public/view/2024-519358-35-00","terms":["PSMA"],"refs":["prostate","tc-99m","psma"]},{"ctNumber":"2026-526519-12-00","title":"A single-arm pilot study to investigate tumor absorbed dose dynamics and feasibility of pre-treatment dosimetry with [177Lu]-PSMA-I&T in male participants aged ≥ 18 years with metastatic castration-resistant prostate cancer","sponsor":"Universitetssykehuset Nord-Norge HF","phase":"Therapeutic exploratory (Phase II)","countries":["Norway"],"conditions":"Metastatic castration-resistant prostate cancer","url":"https://euclinicaltrials.eu/ctis-public/view/2026-526519-12-00","terms":["PSMA"],"refs":["prostate-mcrpc","prostate","lu177-radioligand-therapy","lu-177","psma"]},{"ctNumber":"2023-504696-24-00","title":"The ALPINE trial: a phase 1-2 study of intra-arterial [177Lu]Lu-PSMA-I&T for progressive or recurrent intracranial adult type diffuse glioma","sponsor":"Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)","phase":"Phase I and Phase II (Integrated)- First administration to humans","countries":["Netherlands","Norway"],"conditions":"Glioma (diffuse astrocytoma, oligodendroglioma or glioblastoma)","url":"https://euclinicaltrials.eu/ctis-public/view/2023-504696-24-00","terms":["PSMA"],"refs":["glioblastoma","lu177-radioligand-therapy","lu-177","psma"]},{"ctNumber":"2024-511104-16-00","title":"Molecular theranostics for metastatic prostate cancer: PSMA, FAPI, or both?","sponsor":"Turku University Hospital","phase":"Therapeutic exploratory (Phase II)","countries":["Finland"],"conditions":"Prostate cancer","url":"https://euclinicaltrials.eu/ctis-public/view/2024-511104-16-00","terms":["PSMA"],"refs":["prostate","psma"]},{"ctNumber":"2023-504699-73-00","title":"The evaluation of the effectiveness, safety and tolerability of treatment, using a specialized prostate-specific membrane antigen (PSMA) labeled with Lutetium177, in patients with recurrent and/or metastatic adenoid cystic carcinoma originating from the salivary glands - an open, non-commercial clinical trial","sponsor":"Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie-Panstwowy Instytut Badawczy","phase":"Therapeutic exploratory (Phase II)","countries":["Poland"],"conditions":"Adenoid cystic carcinoma","url":"https://euclinicaltrials.eu/ctis-public/view/2023-504699-73-00","terms":["PSMA"],"refs":["psma"]},{"ctNumber":"2024-514580-26-00","title":"An open label, single-arm, phase 2 study of neoadjuvant PEMbrolizumab before radical PROstatectomy (PEM-PRO) in high-risk prostate cancer patients","sponsor":"Ospedale San Raffaele S.r.l.","phase":"Therapeutic exploratory (Phase II)","countries":["Italy"],"conditions":"High-risk prostate cancer","url":"https://euclinicaltrials.eu/ctis-public/view/2024-514580-26-00","terms":["PSMA"],"refs":["prostate-high-risk","prostate","pembrolizumab"]},{"ctNumber":"2026-525244-14-00","title":"Clinical study to evaluate the safety and efficacy of a new targeted radioactive drug treatment for advanced prostate cancer","sponsor":"Fondazione IRCCS Istituto Nazionale Dei Tumori","phase":"Human Pharmacology (Phase I)- First administration to humans","countries":["Italy"],"conditions":"Metastatic prostate cancer","url":"https://euclinicaltrials.eu/ctis-public/view/2026-525244-14-00","terms":["PSMA"],"refs":["prostate"]},{"ctNumber":"2026-526777-42-00","title":"A Phase 1, Open-Label, Multicenter Study of JANX007 in Subjects with Metastatic Castration-Resistant Prostate Cancer","sponsor":"Janux Therapeutics Inc.","phase":"Human Pharmacology (Phase I)- First administration to humans","countries":["Spain"],"conditions":"Metastatic Castration-Resistant Prostate Cancer","url":"https://euclinicaltrials.eu/ctis-public/view/2026-526777-42-00","terms":["PSMA"],"refs":["prostate-mcrpc","prostate"]},{"ctNumber":"2023-508473-86-00","title":"ExplOratory, Phase 0 Study to assess biodisTribution and PosItron EMission Tomography (PET) Imaging kinetics of [64Cu]Cu-PSMA-R2 in metaStatic prostate cancEr patients","sponsor":"Institut De Cancerologie De L Ouest","phase":"Human Pharmacology (Phase I)- Other","countries":["France"],"conditions":"metastatic prostate cancer","url":"https://euclinicaltrials.eu/ctis-public/view/2023-508473-86-00","terms":["PSMA"],"refs":["prostate","psma","cu-64"]},{"ctNumber":"2025-521551-23-01","title":"Sequential Chemotherapy regimen with vinorelbine and cisplatin plus PET-guided stereotactic ablative radiotherapy (SABR) for castration- and taxane-resistant Prostate cancer (ChemSABR Prostate)","sponsor":"Tartu University Hospital","phase":"Phase I and Phase II (Integrated)- Other","countries":["Estonia"],"conditions":"prostate cancer","url":"https://euclinicaltrials.eu/ctis-public/view/2025-521551-23-01","terms":["PSMA"],"refs":["prostate"]}]},"research":{"source":"https://www.ebi.ac.uk/europepmc/webservices/rest/search","window":{"from":"2025-10-23","to":"2026-10-23"},"query":"(radioligand OR radiopharmaceutical OR theranostic OR \"nuclear medicine\" OR radionuclide) AND AFF:\"<country>\" AND FIRST_PDATE:[2025-10-23 TO 2026-10-23]","worldwide":23614,"countries":[{"country":"China","count":6971,"newest":[{"title":"Advances and perspectives in genetically encoded biosensors for biomarker detection and theranostic circuits.","journal":"Synth Syst Biotechnol","date":"2026-09-23","doi":"10.1016/j.synbio.2026.09.006","url":"https://doi.org/10.1016/j.synbio.2026.09.006"},{"title":"Theranostic peptide-selenium hydrogel targeting NETs-mitochondrial dysfunction-pyroptosis axis for chronic diabetic wound repair.","journal":"Bioact Mater","date":"2026-09-22","doi":"10.1016/j.bioactmat.2026.09.022","url":"https://doi.org/10.1016/j.bioactmat.2026.09.022"},{"title":"Calcium dysregulation in synergy with sonodynamic therapy via medroxyprogesterone-targeted and ROS-responsive nanoparticles for endometrial cancer.","journal":"Bioact Mater","date":"2026-09-23","doi":"10.1016/j.bioactmat.2026.09.017","url":"https://doi.org/10.1016/j.bioactmat.2026.09.017"},{"title":"Color-tunable, water-stable room-temperature phosphorescent carbon dot-based Nanoplatform for intelligent tumor theranostics with self-monitoring of drug release.","journal":"J Colloid Interface Sci","date":"2026-09-20","doi":"10.1016/j.jcis.2026.141648","url":"https://doi.org/10.1016/j.jcis.2026.141648"},{"title":"Dynamic coordination engineering of gallium biomaterials: A biological accessibility framework for therapeutic biofunction.","journal":"Bioact Mater","date":"2026-09-17","doi":"10.1016/j.bioactmat.2026.09.008","url":"https://doi.org/10.1016/j.bioactmat.2026.09.008"}]},{"country":"Germany","count":2318,"newest":[{"title":"Multifunctional theranostic nanocarrier platform for microglia-selective cytochalasin D delivery to modulate neuroinflammation after acute brain injuries.","journal":"Biomaterials","date":"2026-07-29","doi":"10.1016/j.biomaterials.2026.124495","url":"https://doi.org/10.1016/j.biomaterials.2026.124495"},{"title":"Whole heart atherosclerosis volume and risk for major adverse cardiovascular events across the clinical likelihood for obstructive CAD; the CONFIRM2 study.","journal":"Am J Prev Cardiol","date":"2026-06-24","doi":"10.1016/j.ajpc.2026.101712","url":"https://doi.org/10.1016/j.ajpc.2026.101712"},{"title":"Integrating visual state space models with frequency selection for artifact reduction in photoacoustic tomography.","journal":"Photoacoustics","date":"2026-09-26","doi":"10.1016/j.pacs.2026.100888","url":"https://doi.org/10.1016/j.pacs.2026.100888"},{"title":"Identifying sleep profiles in patients with an implantable cardioverter-defibrillator: associations with psychological distress.","journal":"J Psychosom Res","date":"2026-09-19","doi":"10.1016/j.jpsychores.2026.113000","url":"https://doi.org/10.1016/j.jpsychores.2026.113000"},{"title":"Corrigendum to: ''Induction of cytochromes P450 1A1 and 1A2 suppresses formation of DNA adducts by carcinogenic aristolochic acid I in rats in vivo'' [Toxicology 344-346 (2016) 7-18].","journal":"Toxicology","date":"2026-09-09","doi":"10.1016/j.tox.2026.154576","url":"https://doi.org/10.1016/j.tox.2026.154576"}]},{"country":"Italy","count":1587,"newest":[{"title":"Whole heart atherosclerosis volume and risk for major adverse cardiovascular events across the clinical likelihood for obstructive CAD; the CONFIRM2 study.","journal":"Am J Prev Cardiol","date":"2026-06-24","doi":"10.1016/j.ajpc.2026.101712","url":"https://doi.org/10.1016/j.ajpc.2026.101712"},{"title":"Hip and groin pain in physically active adults with a focus on terminology, clinical examination and imaging: A formal ESSKA-EHPA-ESMA Consensus.","journal":"Knee Surg Sports Traumatol Arthrosc","date":"2026-09-07","doi":"10.1002/ksa.70565","url":"https://doi.org/10.1002/ksa.70565"},{"title":"Sleep disorders in adults with Cri du Chat syndrome: A questionnaire-based study.","journal":"Sleep Med","date":"2026-09-04","doi":"10.1016/j.sleep.2026.109250","url":"https://doi.org/10.1016/j.sleep.2026.109250"},{"title":"[<sup>177</sup>Lu] Lu-PSMA-I&T for prostate cancer radioligand therapy: A radiopharmacy's journey from synthesis to cost-effectiveness.","journal":"Appl Radiat Isot","date":"2026-08-25","doi":"10.1016/j.apradiso.2026.112855","url":"https://doi.org/10.1016/j.apradiso.2026.112855"},{"title":"Challenging bone biopsies: what radiologists needs to know.","journal":"Skeletal Radiol","date":"2026-08-10","doi":"10.1007/s00256-026-05336-7","url":"https://doi.org/10.1007/s00256-026-05336-7"}]},{"country":"India","count":1150,"newest":[{"title":"Muscle oxygen saturation (SmO<sub>2</sub>): An upstream metabolic link connecting peripheral muscle metabolism to central neurobiological adaptations.","journal":"Neurosci Biobehav Rev","date":"2026-10-05","doi":"10.1016/j.neubiorev.2026.107022","url":"https://doi.org/10.1016/j.neubiorev.2026.107022"},{"title":"Multimodality imaging localization of a giant functional parathyroid adenoma in a young fitness trainer with delayed recognition of hypercalcemia: A case report.","journal":"Radiol Case Rep","date":"2026-09-12","doi":"10.1016/j.radcr.2026.08.067","url":"https://doi.org/10.1016/j.radcr.2026.08.067"},{"title":"Automated radiochemical synthesis of [<sup>68</sup>Ga]Ga-FAPI-4 employing modular lab standard with fixed-tubing non-cassette methodology: its preliminary clinical feasibility.","journal":"Appl Radiat Isot","date":"2026-09-01","doi":"10.1016/j.apradiso.2026.112899","url":"https://doi.org/10.1016/j.apradiso.2026.112899"},{"title":"Unlocking exosome potential: Comprehensive review on diagnostic, prognostic and therapeutic approaches in melanoma.","journal":"Colloids Surf B Biointerfaces","date":"2026-08-18","doi":"10.1016/j.colsurfb.2026.116100","url":"https://doi.org/10.1016/j.colsurfb.2026.116100"},{"title":"Present status of prostate cancer diagnosis, limitations, challenges, and future endeavors.","journal":"Ann Med","date":"2026-08-03","doi":"10.1080/07853890.2026.2659984","url":"https://doi.org/10.1080/07853890.2026.2659984"}]},{"country":"France","count":1031,"newest":[{"title":"Acid-responsive nanoparticles with microneedles for anti‑inflammatory sonodynamic therapy of gouty arthritis.","journal":"Drug Deliv","date":"2026-10-13","doi":"10.1080/10717544.2026.2743337","url":"https://doi.org/10.1080/10717544.2026.2743337"},{"title":"Identification of PfSR1-MT as melatonin-responsive GPCR-like candidate from the human malaria parasite <i>Plasmodium falciparum</i>.","journal":"Curr Res Microb Sci","date":"2026-09-13","doi":"10.1016/j.crmicr.2026.100663","url":"https://doi.org/10.1016/j.crmicr.2026.100663"},{"title":"International Western Radiation Therapy Guidelines Applicability in Low- and Middle-Income Countries for Cervical Cancer Management: A Comparative Survey Example from South and North Border of the Mediterranean Area Countries.","journal":"Adv Radiat Oncol","date":"2026-09-12","doi":"10.1016/j.adro.2026.102154","url":"https://doi.org/10.1016/j.adro.2026.102154"},{"title":"Hip and groin pain in physically active adults with a focus on terminology, clinical examination and imaging: A formal ESSKA-EHPA-ESMA Consensus.","journal":"Knee Surg Sports Traumatol Arthrosc","date":"2026-09-07","doi":"10.1002/ksa.70565","url":"https://doi.org/10.1002/ksa.70565"},{"title":"Inhibition of Aryl hydrocarbon receptor Interleukin-22 signaling and worsening of intestinal inflammation by <i>Sutterella</i> species.","journal":"Gut Microbes","date":"2026-06-21","doi":"10.1080/19490976.2026.2690688","url":"https://doi.org/10.1080/19490976.2026.2690688"}]},{"country":"Japan","count":979,"newest":[{"title":"Two Contrasting Scintigraphy-Negative Pediatric Meckel's Diverticula Identified and Localized by Intestinal Ultrasound and Double-Balloon Enteroscopy: A Report of Two Cases.","journal":"DEN Open","date":"2026-07-13","doi":"10.1002/deo2.70379","url":"https://doi.org/10.1002/deo2.70379"},{"title":"Whole heart atherosclerosis volume and risk for major adverse cardiovascular events across the clinical likelihood for obstructive CAD; the CONFIRM2 study.","journal":"Am J Prev Cardiol","date":"2026-06-24","doi":"10.1016/j.ajpc.2026.101712","url":"https://doi.org/10.1016/j.ajpc.2026.101712"},{"title":"Cancer cell membrane-coated superparamagnetic iron oxide nanoparticles as a theranostic platform for magnetic hyperthermia and MR imaging.","journal":"Bioorg Med Chem","date":"2026-08-25","doi":"10.1016/j.bmc.2026.118787","url":"https://doi.org/10.1016/j.bmc.2026.118787"},{"title":"Spatial distribution of fibroblastic foci in transbronchial lung cryobiopsy specimens.","journal":"Ann Diagn Pathol","date":"2026-08-21","doi":"10.1016/j.anndiagpath.2026.152706","url":"https://doi.org/10.1016/j.anndiagpath.2026.152706"},{"title":"Dissolving microneedles for inflammatory diseases: Advances in formulation strategies and therapeutic applications.","journal":"Int J Pharm X","date":"2026-07-28","doi":"10.1016/j.ijpx.2026.100623","url":"https://doi.org/10.1016/j.ijpx.2026.100623"}]},{"country":"Korea","count":823,"newest":[{"title":"A product control framework for extracellular vesicle therapeutics: Quality attributes, stability, analytical procedures, and biodistribution.","journal":"Int J Pharm X","date":"2026-08-25","doi":"10.1016/j.ijpx.2026.100650","url":"https://doi.org/10.1016/j.ijpx.2026.100650"},{"title":"Direct low-energy gamma-ray measurement of <sup>129</sup>I in radioactive waste using LEGe spectrometry and evaluation of the minimum detectable activity.","journal":"Appl Radiat Isot","date":"2026-08-26","doi":"10.1016/j.apradiso.2026.112888","url":"https://doi.org/10.1016/j.apradiso.2026.112888"},{"title":"Development of a mobile high-intensity focused ultrasound platform for preclinical tumor microenvironment modulation in a pancreatic ductal adenocarcinoma mouse model.","journal":"Int J Hyperthermia","date":"2026-08-17","doi":"10.1080/02656736.2026.2716349","url":"https://doi.org/10.1080/02656736.2026.2716349"},{"title":"crossMoDA challenge: Evolution of cross-modality domain adaptation techniques for vestibular schwannoma and cochlea segmentation from 2021 to 2023.","journal":"Med Image Anal","date":"2026-08-24","doi":"10.1016/j.media.2026.104282","url":"https://doi.org/10.1016/j.media.2026.104282"},{"title":"Quercetin and lupeol accelerate keratinocyte wound healing by dual modulation of GLP-1 receptor activity and stability.","journal":"Life Sci","date":"2026-08-24","doi":"10.1016/j.lfs.2026.124644","url":"https://doi.org/10.1016/j.lfs.2026.124644"}]},{"country":"Spain","count":790,"newest":[{"title":"Dynamic coordination engineering of gallium biomaterials: A biological accessibility framework for therapeutic biofunction.","journal":"Bioact Mater","date":"2026-09-17","doi":"10.1016/j.bioactmat.2026.09.008","url":"https://doi.org/10.1016/j.bioactmat.2026.09.008"},{"title":"External validation of the RAISE score for the diagnosis of transthyretin cardiac amyloidosis in patients with severe aortic stenosis. AMYLOCOR registry.","journal":"Int J Cardiol","date":"2026-09-17","doi":"10.1016/j.ijcard.2026.134787","url":"https://doi.org/10.1016/j.ijcard.2026.134787"},{"title":"Hip and groin pain in physically active adults with a focus on terminology, clinical examination and imaging: A formal ESSKA-EHPA-ESMA Consensus.","journal":"Knee Surg Sports Traumatol Arthrosc","date":"2026-09-07","doi":"10.1002/ksa.70565","url":"https://doi.org/10.1002/ksa.70565"},{"title":"Differential Trajectories of Brain Atrophy in Multiple Sclerosis, MOGAD, and AQP4 + NMOSD: The Role of Disease Activity in MOGAD.","journal":"Neurology","date":"2026-10-20","doi":"10.1212/wnl.0000000000218673","url":"https://doi.org/10.1212/wnl.0000000000218673"},{"title":"PSMA PET/CT Kinetics During Systemic Therapy and Radiotherapy in Hormone-sensitive Prostate Cancer: A Systematic Review.","journal":"Eur Urol Open Sci","date":"2026-09-21","doi":"10.1016/j.euros.2026.09.003","url":"https://doi.org/10.1016/j.euros.2026.09.003"}]},{"country":"Turkey","count":425,"newest":[{"title":"Magnetically responsive electrospun fibers as programmable bioactive scaffolds: From formulation design to magnetically triggered therapy and regeneration.","journal":"Bioact Mater","date":"2026-08-12","doi":"10.1016/j.bioactmat.2026.08.014","url":"https://doi.org/10.1016/j.bioactmat.2026.08.014"},{"title":"Circadian timing of first-line chemoimmunotherapy is associated with survival in extensive-stage small cell lung cancer.","journal":"Oncoimmunology","date":"2026-09-25","doi":"10.1080/2162402x.2026.2738262","url":"https://doi.org/10.1080/2162402x.2026.2738262"},{"title":"Hip and groin pain in physically active adults with a focus on terminology, clinical examination and imaging: A formal ESSKA-EHPA-ESMA Consensus.","journal":"Knee Surg Sports Traumatol Arthrosc","date":"2026-09-07","doi":"10.1002/ksa.70565","url":"https://doi.org/10.1002/ksa.70565"},{"title":"Bio-based nanomaterials in drug delivery: An updated review.","journal":"Pharm Sci Adv","date":"2026-05-22","doi":"10.1016/j.pscia.2026.100126","url":"https://doi.org/10.1016/j.pscia.2026.100126"},{"title":"Toxicity of nanostructures in drug delivery applications.","journal":"Pharm Sci Adv","date":"2026-03-20","doi":"10.1016/j.pscia.2026.100117","url":"https://doi.org/10.1016/j.pscia.2026.100117"}]},{"country":"Brazil","count":336,"newest":[{"title":"Whole heart atherosclerosis volume and risk for major adverse cardiovascular events across the clinical likelihood for obstructive CAD; the CONFIRM2 study.","journal":"Am J Prev Cardiol","date":"2026-06-24","doi":"10.1016/j.ajpc.2026.101712","url":"https://doi.org/10.1016/j.ajpc.2026.101712"},{"title":"Preclinical evaluation of PSMA-targeted ultrasound contrast agents in an orthotopic model of prostate cancer in rabbits.","journal":"Bioact Mater","date":"2026-08-11","doi":"10.1016/j.bioactmat.2026.07.040","url":"https://doi.org/10.1016/j.bioactmat.2026.07.040"},{"title":"Identification of PfSR1-MT as melatonin-responsive GPCR-like candidate from the human malaria parasite <i>Plasmodium falciparum</i>.","journal":"Curr Res Microb Sci","date":"2026-09-13","doi":"10.1016/j.crmicr.2026.100663","url":"https://doi.org/10.1016/j.crmicr.2026.100663"},{"title":"Hydroforming assembly of annular metallic uranium foil targets for Mo-99 production.","journal":"Appl Radiat Isot","date":"2026-09-01","doi":"10.1016/j.apradiso.2026.112887","url":"https://doi.org/10.1016/j.apradiso.2026.112887"},{"title":"Evaluation of maternal and fetal S-values from iodine isotopes in nuclear medicine using the Monte Carlo method.","journal":"Appl Radiat Isot","date":"2026-08-25","doi":"10.1016/j.apradiso.2026.112886","url":"https://doi.org/10.1016/j.apradiso.2026.112886"}]},{"country":"Taiwan","count":282,"newest":[{"title":"Transcranial microbubble-enhanced ultrafast Doppler imaging of ultrasound-induced brain stimulation using a dual-mode concave low-frequency array transducer.","journal":"Ultrasonics","date":"2026-09-06","doi":"10.1016/j.ultras.2026.108284","url":"https://doi.org/10.1016/j.ultras.2026.108284"},{"title":"Blood transcriptomic signatures distinguish <i>Mycobacterium avium</i> complex pulmonary disease from colonization: a multicenter cohort study.","journal":"Emerg Microbes Infect","date":"2026-06-04","doi":"10.1080/22221751.2026.2678657","url":"https://doi.org/10.1080/22221751.2026.2678657"},{"title":"2024 International expert consensus on ultrasound-guided thermal ablation for secondary and tertiary hyperparathyroidism.","journal":"Int J Hyperthermia","date":"2026-01-28","doi":"10.1080/02656736.2025.2606698","url":"https://doi.org/10.1080/02656736.2025.2606698"},{"title":"Back diffusion of a Th-230-Ra-226 decay chain in a multilayer fractured-rock matrix with stagnant-zone and skin effects.","journal":"J Contam Hydrol","date":"2026-08-30","doi":"10.1016/j.jconhyd.2026.105099","url":"https://doi.org/10.1016/j.jconhyd.2026.105099"},{"title":"Persistent Colonic Activity on 99m Tc-MDP Whole Bone Scintigraphy Revealing a Complex Ureterorectal Fistula.","journal":"Clin Nucl Med","date":"2026-08-17","doi":"10.1097/rlu.0000000000006666","url":"https://doi.org/10.1097/rlu.0000000000006666"}]},{"country":"Russia","count":173,"newest":[{"title":"Automated segmentation and clinical characterization of layered plaque in intracoronary optical coherence tomography.","journal":"Int J Cardiol Heart Vasc","date":"2026-10-09","doi":"10.1016/j.ijcha.2026.102025","url":"https://doi.org/10.1016/j.ijcha.2026.102025"},{"title":"Unexpected ¹⁸F-DOPA Uptake in Pediatric Posterior Mediastinal Ewing Sarcoma: A Diagnostic Pitfall in Pediatric Oncology.","journal":"Clin Nucl Med","date":"2026-09-04","doi":"10.1097/rlu.0000000000006687","url":"https://doi.org/10.1097/rlu.0000000000006687"},{"title":"Preparation of <sup>59</sup>Fe-labelled magnetite nanoparticles with iron sulphates and by direct neutron activation.","journal":"Appl Radiat Isot","date":"2026-08-10","doi":"10.1016/j.apradiso.2026.112852","url":"https://doi.org/10.1016/j.apradiso.2026.112852"},{"title":"Automated segmentation and clinical characterization of layered plaque in intracoronary optical coherence tomography","journal":"Int J Cardiol Heart Vasc","date":"2026-10-09","url":"https://europepmc.org/article/PMC/PMC13677019"},{"title":"RETRACTED: Tishkevich et al. Magnetic Properties of the Densely Packed Ultra-Long Ni Nanowires Encapsulated in Alumina Membrane. <i>Nanomaterials</i> 2021, <i>11</i>, 1775.","journal":"Nanomaterials (Basel)","date":"2026-10-07","doi":"10.3390/nano16191262","url":"https://doi.org/10.3390/nano16191262"}]}]}}